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Abstract 
More than 883 extracellular proteins that bind heparan sulfate (HS) and heparin have 
been identified whose activities are regulated by their interactions with these 
polysaccharides. FGFs are heparin-binding proteins (the physiological ligand is HS) 
and the interactions of FGF with HS determine their transport between cells and the 
assembly of signalling complexes with their cognate receptor tyrosine kinases, 
FGFRs. The FGF family has expanded from two or three FGF ligands in the worm 
C. elegans and the fly Drosophila to 18 FGFs in vertebrates and mammals, which is 
directly linked to the more complex specifications required in the development for 
increasingly complex body parts. However, the level of specificity of the interaction 
of FGFs with HS is still debated. Previous work generally focused on just one or two 
FGFs and a limited repertoire of sugar structures, so a systematic investigation of the 
interaction of FGFs with heparin/HS is required to determine at what level, if any, 
there is specificity at the molecular level underlying these interactions. The strategy 
of this work was to use the evolutional relationship of the FGF family as a defined 
system to explore the specificity of interactions of FGFs and heparin/HS. Six FGFs 
(FGF3, FGF4, FGF6, FGF10, FGF17, and FGF20) from 4 subfamilies have been 
produced and purified as recombinant proteins, to investigate the interaction between 
FGFs and HS from two different perspectives. The polysaccharide structure required 
for binding to the FGFs was determined by differential scanning fluorimetry (DSF) 
using a library of chemically modified heparins and model glycosaminoglycans. The 
heparin binding sites on the FGFs were then identified by a lysine selective 
technique called ‘protect and label’. For systemic analysis of the interactions, all of 
the results obtained have been mapped on the FGF evolutionary tree deduced amino 
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acid sequence alignment, alongside previous work. This shows a clear pattern: FGF 
members from the same subfamily have a similar preference for binding particular 
subsets of HS/heparin structures and model glycosaminoglycans, and share similar 
secondary heparin binding sites on their surface. In contrast, FGFs from different 
subfamilies have a more divergent preference for binding structures in the 
polysaccharide and secondary binding sites on their surface. The secondary heparin 
binding sites (HBS) of FGF2 were mutated to begin the characterization of their 
functions. The properties of the mutants of FGF2’s secondary HBSs (HBS2, HBS3) 
were measured in terms of their preference for binding structures in heparins, their 
ability to stimulate the phosphorylation of p42/44
MAPK
 and cell proliferation. FGF2 
(HBS2) mutant was found to be distinct to wild-type only in its interactions with low 
sulfated heparins where mutant FGF2 (HBS2) exhibited a stronger preference for N-
sulfated heparin. For mutant FGF2 (HBS3), a larger sugar structure was required for 
binding than wild type FGF2. Finally, since both lysine and arginine residues in 
HBSs contribute to the interaction between protein and polysaccharide, an arginine 
targeted protect and label method was developed. Phenylglyoxal (PGO) was 
successfully used in the protection step and was demonstrated to be capable of 
achieving full arginine labelling. However, arginine labelling with 4-
azidophenylglyoxal (APG) suffered from a ring expansion side reaction and this 
second step still needs to be optimized. Overall the thesis demonstrates that there is 
specificity in the interaction of FGFs and glycosaminoglycans. Although this is not a 
simple one-to-one code, it has clearly been subjected to the same natural selection 
that led to the expansion and diversification of the FGF family, the specificities of 
FGFs for particular isoforms of the FGFRs and selective activities of the FGF family 
in specifying the different structures and organs of the mammalian body. 
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Chapter 1 General Introduction 
1.1 The discovery of FGFs 
In 1974, the term fibroblast growth factor (FGF) was first used by Gospodarowicz to 
describe a polypeptide found in pituitary and in brain that stimulated the initiation of 
DNA synthesis in resting 3T3 fibroblasts
 [1]
. This was purified from both of these 
sources and was termed basic FGF (bFGF), because the protein was basic and 
stimulated mitogenesis in 3T3fibroblasts 
[2, 3]
. Subsequently, brain tissue was found 
to also contain a second molecule with FGF activity, which was called acidic FGF 
(aFGF), because its isoelectric point was the opposite to that of bFGF’s [4]. 
Thereafter, additional FGFs were identified and isolated by a variety of methods. 
According to the number-based nomenclature system, aFGF and bFGF were 
renamed as FGF1 and FGF2, respectively. FGF3 (int-2) 
[5]
, FGF4 (kFGF/hst) 
[6]
, 
FGF5 
[7]
 and FGF6 
[8] 
were originally isolated as oncogene products. FGF7 was 
identified as keratinocyte growth factor (KGF) with the distinctive properties of a 
mesenchyme-derived stimulator of epithelial cell growth 
[9]
. FGF8 was isolated and 
characterized as causing unusual male sex hormone-dependent growth of mouse 
mammary carcinoma cells 
[10]
. After a series of analyses of cDNA structure, 
Miyamoto et al. determined that glia-activating factor (GAF) was the ninth member 
of the FGF family, FGF9 
[11]
. FGF10 was isolated from rat embryos by homology-
based polymerase chain reaction (PCR) 
[12]
. Four further members of the FGF family, 
called FGF homologous factors (FHFs), FGF11 (FHF3), FGF12 (FHF1), FGF13 
(FHF2) and FGF14 (FHF4) were found by a combination of random cDNA 
sequencing, data base searches, and degenerate PCR 
[13]
. Following this, the Itoh 
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laboratory successfully isolated and identified FGF16, FGF17, FGF18, FGF20, and 
FGF21 by homology-based polymerase chain reaction
 [14], [15], [16], [17], [18]
. FGF19, 
FGF22 and FGF23 were originally isolated by searching genome data bases 
[19], [20], 
[21]
. Parallel discovery, allied to rapid analysis following completion of the human 
genome project resulted in the finding that human FGF19 correspond to mouse 
FGF15; there is no human FGF15 or mouse FGF19 
[22]
. 
 
1.2 Evolution of the FGF gene family  
The fgf genes have not been found in unicellular organisms such as Escherichia coli 
and Saccharomyces cerevisiae. After sequencing of the Caenorhabditis elegans and 
Drosophila genomes, two (egl-17 and let-756) and three (branch-less, pyramus and 
thisbe) FGF genes were identified, respectively 
[23-27]
. Six fgf-like genes were then 
identified in a basal chordate, the ascidian Ciona intesinalis that are considered to be 
potential ancestral genes of human FGF subfamilies, which include fgf4-like, fgf5-
like, fgf8-like, fgf9-like, fgf10-like and fgf13-like 
[28]
. Twenty-two fgf genes have been 
identified in the human, mouse and zebra fish fgf families 
[29]
. The ancestral genes of 
fgf gene subfamilies have been hypothesized to be the result of gene duplication 
following the divergence of protostomes and deuterostomes 
[30]
. A model of the 
evolutionary history of the fgf gene family has proposed that gene expansion presents 
in two phases (Fig. 1.1). In the first phase, there was gene duplication of the fgf gene 
from two or three to six genes during the early evolution of metazoans. In the second 
phase, the full complement of vertebrate genes was generated by two large-scale 
genome duplications 
[30, 31]
. 
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Figure 1.1 Possible evolutionary relationships between the fgf genes. The fgf13-
like is the ancestral gene of the whole fgf gene family. The fgf4-like was generated by 
gene duplication from fgf13-like at an early stage. In the first phase (phase I), fgf5-
like, fgf8-like, fgf9-like, fgf10-like and fgf15/19-like were generated by gene 
duplication. All of these expanded into three or four members by two large-scale 
gene duplications during phase II.  
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1.3 Phylogenetic and gene location analysis of the 
human/mouse fgf gene family 
The fgf evolutionary relationship has been determined by the analysis of gene 
location on chromosomes 
[29, 30, 32, 33]
. Seven fgf subfamilies have been suggested by 
gene location analysis: fgf1, fgf2 and fgf5; fgf3, fgf4 and fgf6; fgf7, fgf10 and fgf22; 
fgf8, fgf17 and fgf18; fgf9, fgf16 and fgf20; fgf11, fgf12, fgf13 and fgf14; fgf15/19, 
fgf21 and fgf2 (Fig 1.1). 
Apart from gene location analysis, phylogenetic analysis has also been applied to 
determine the relationship of FGFs from their amino acid sequence (Fig 1.2) and also 
indicates that there are seven subfamilies: fgf1 and fgf2 (fgf 1 subfamily); fgf4, fgf5 
and fgf6 (fgf4 subfamily); fgf3, fgf7, fgf10 and fgf22 (fgf7 subfamily); fgf8, fgf17 and 
fgf18 (fgf8 subfamily); fgf9, fgf16 and fgf20 (fgf9 subfamily); fgf11, fgf12, fgf13 and 
fgf14 (fgf11 subfamily); fgf15/19, fgf21, and fgf23 (fgf19 subfamily) (Fig. 1.2). The 
members of the fgf8, fgf9, fgf11 and fgf19 subfamilies are consistent with the 
phylogenetic and gene location analyses. However, fgf5 and fgf3 are indicated to be 
members of fgf4 subfamily and fgf7 subfamily, respectively, by phylogenetic 
analysis. The phylogenetic relationship based on sequence maps to functional 
similarities of the FGFs 
[34, 35]
 and it is in this context that FGF subfamilies will be 
discussed here. 
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Figure 1.2 Evolutionary relationship tree of FGF family. According to amino 
acid sequence, Dendroscope was used to show that FGF family is divided into seven 
subfamilies. The branch lengths relate directly to the evolutionary relationship of 
FGFs.  
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1.4 FGF ligands 
1.4.1 FGF ligand structure  
The molecular weights of the FGFs range from 17 to 34 kDa in vertebrates, whereas 
it reaches 84 kDa in Drosophila. All FGFs share an internal core of similar structure 
with 28 highly conserved, and 6 invariant amino acid residues 
[36]
. X-ray 
crystallography of FGFs shows that the FGF family possesses a similar folding 
pattern to the interleukins IL-1β and IL-1α [37]. FGFs possess a β trefoil structure, 
which is formed by three sets of four β strands connected by loops (Fig. 1.3) [38]. A 
variety of studies have demonstrated that the primary heparin binding site of FGF2 is 
formed by the strand β1/β2 loop, strands β10 / β11 loop, strand β11 and strands β11 / 
β12 loop (Fig. 1.4) [38-42]. The receptor tyrosine kinase (FGFR) binding site involves 
the strand β8-β9 loop and is distinct from the heparin binding site. This suggests that 
receptor binding and the binding of heparin and HS are likely to be physically 
separated 
[22, 31, 38]
.  
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Figure 1.3 Schematic diagram of the core structure unit of the β-trefoil motif. 
The first ascending strand (βA) is connected to a descending strand (βB). The 
following “horizontal” strand (βC) is connected to the return strand (βD). Three of 
these units arranged around a pseudo three fold axis of symmetry form the β trefoil. 
                 
Figure 1.4 Ribbon diagram of crystal structure of FGF2. PDB ID: 2FGF 
[38]
. The 
β trefoil structure is made up of 12 anti-parallel β strands. The structure of FGF2 was 
generated from the crystallographic coordinates with PyMol. The heparin binding 
sites are highlighted in black. The FGFR binding site is highlighted in blue. 
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1.4.2 The functions of FGFs  
According to their mechanism of action, FGF activities can be classified into three 
types: intracrine, paracrine and endocrine. The paracrine FGF subfamilies are the 
FGF1 and FGF2; FGF3, FGF7, FGF10 and FGF22; FGF4, FGF5 and FGF6; FGF8, 
FGF17 and FGF18; FGF 9, FGF16 and FGF20. Most of these members of the FGF 
family have a cleavable N-terminal secretory signal peptide for export through the 
classical endoplasmic reticulum (ER)/ Golgi pathway. However, FGF1 and FGF2, 
which have no secretory signal peptide and have been shown to be exported from 
cells through mechanisms independent of the conventional endoplasmic reticulum - 
Golgi pathway 
[43-46]
. Although members of FGF9 subfamily share the classical 
secretory pathway, they do not have a cleavable signal sequence. Instead, they 
possess a bipartite secretory signal sequence for their interaction with the secretory 
machinery 
[47, 48]
.  
The paracrine FGFs all bind strongly to HS, a major glycosaminoglycan in 
pericellular and extracellular matrix, through their heparin binding sites. This 
interaction limits their radius of diffusion so consequently these FGFs exert their 
biological effects near their source of synthesis. The intracrine FGFs are the 
members of the FGF11 subfamily that are expressed in cells as intracellular proteins. 
The intracrine FGFs have been shown to have a crucial role in regulation of the 
excitability of granule neurons 
[49, 50]
. The FGF19 subfamily members have weak or 
no binding to HS, so are able to perform their function in an endocrine manner 
[51]
. 
They use α and β-Klotho as their co-receptor to bind to their cognate receptors [52-54]. 
Most fgf genes have been knocked out in mouse and the phenotypes indicate that in 
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this context they all have at least one non-redundant biological function (Table 1.1) 
[33, 55, 56]
. 
 
Table 1.1 Summary of some physiological roles of FGF. 
 
Reference for each FGF (FGF1 
[56]
; FGF2 
[57-62]
; FGF3 
[63]
; FGF4 
[64-66]
; FGF5 
[67-69]
; 
FGF6 
[70, 71]
; FGF7 
[72, 73]
; FGF8 
[74-76]
; FGF9 
[77, 78]
; FGF10 
[79]
; FGF16 
[80]
; FGF17 
[81]
; FGF18 
[82, 83]
; FGF19 
[84-88]
; FGF20 
[89]
; FGF21 
[90-94]
; FGF22 
[95]
; FGF23 
[96-101]
). 
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1.5 Heparin/Heparan sulfate  
1.5.1 Heparin/heparan sulfate structure 
Heparan sulfate (HS) is a member of the family of glycosaminoglycans (GAGs), 
containing repeating disaccharide units joined by 1-4 linkages. As well as HS, the 
GAG family includes hyaluronic acid (HA), chondroitin sulfate (CS), dermatan 
sulfate (DS) and keratan sulfate (KS). The complex structure of HS distinguishes it 
from other GAGs 
[102]
.  The repeating units of HS consist of a glucuronic acid (β-D-
GlcA) or its C5-epimer α-L-IdoA, and α-D-glucosamine (GlcN). The glucosamine 
may be N-acetylated (GlcNAc), N-sulfated (GlcNS), or unsubstituted (GlcN). O-
sulfation can occur at position 2 of the uronic acid and position 3 and 6 of the 
glucosamine (Fig. 1.5). Heparin shares the same repeating disaccharide units as HS, 
but presents a far more homogeneous and higher level of sulfation 
[103]
. Since it 
shares similarity in structure and is commercially available, heparin or its derivatives 
are often used as models for HS in studies of sugar-protein interactions 
[104]
.  
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Figure 1.5 Heparin/HS disaccharide units. The repeating units of HS consist of a 
uronic acid (β-D-GlcA) or its C5-epimer α-L-IdoA, and D-glucosamine (α-GlcN). R1 
can be H, COCH3 or SO3
- 
; R2/3/4 can be H or SO3
-
. 
 
1.5.2 Heparin/HS biosynthesis 
The pathway of biosynthesis of HS can be divided into three sets of reactions: chain 
initiation, chain polymerization and polymer modification. Its biosynthesis occurs in 
the Golgi apparatus and begins with a linker tetrasaccharide being assembled on a 
specific serine residue of newly translated core proteins. Subsequently, the 
polymerization of the heparin/HS chain is performed by alternate addition of 
glucuronic acid and N-acetyl glucosamine to the non-reducing end of the growing 
polysaccharide. The repeated addition of these two saccharides is catalyzed by the 
tumor suppressor EXT family genes (EXT1 and EXT2) that form a stable 
heterodimeric complex 
[105, 106]
. Afterwards, the sugar chain undergoes various 
modifications carried out by a series of enzymes. Firstly, the dual activity of the N-
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deacetylase / N-sulfotransferases (NDSTs) catalyses the replacement of the N-acetyl 
group of glucosamine with a sulfate group. The presence of N-sulfate marks this 
disaccharide and the adjacent ones for further modifications. The C5 epimerization 
of glucuronic acid to iduronic acid through the C5 epimerase has been shown to only 
happen to the GlcA substrate that is attached to the reducing end of a GlcNS residue 
[107]
. O-sulfation can then take place on position 2 of the uronic acid and position 3 
and 6 of the glucosamine, catalysed by 2-O, 3-O and the 6-O sulfotransferases 
[108, 
109]
. Any GlcNS can be the substrate for 6-O sulfotransferases, whereas the 2-O-
sulfotransferases cannot modify the IdoA attached to GlcNS(6S), which indicates 
that the 6-O-sulfation of GlcNS follows the 2-O-sulfation of IdoA 
[110]
. The action of 
the N-deacetylase / N-sulfotransferases (NDSTs) is clustered. Thus, they will ignore 
a sequence of saccharide, and then act on alternating disaccharides, followed by 
every sequential disaccharide, and then alternating ones and so on. Since all the other 
modifications depend on the presence of N-sulfated glucosamine, the result is that 
HS chains have a domain structure: NA domains with no sulfation structure, NS 
domains of highly sulfated structures, and NA/NS domains comprising mixed 
regions of GlcNAc and GlcNS. The sulfated structures are of functional significance, 
forming the protein binding sites. Heparin chains contain more GlcNS residues than 
HS (the ratio of GlcNS to GlcNAc is around 4:1 in heparin and 1:1 in HS) and also 
contain more sulfated structures at an average of 2.4 sulfates/disaccharide than HS, 
which has O-sulfate structures in the range of 0.2-0.7 O-sulfate/disaccharide 
[103]
. 
The sequential application of the biosynthetic enzymes does not readily explain such 
disaccharides as GlcA-GlcNAc6s or IdoA-GlcNAc6s, which have been found. An 
alternative view, implying enzymes capable of such conversion, has been proposed 
based on removal substrate specificities 
[111]
.  
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1.5.3 The functions of Heparin/HS 
The HS chains are always synthesized attached to a core protein to form heparan 
sulfate proteoglycans (HSPGs) 
[112]
. It is the core protein that directs the HS chains to 
specific locations, the cell surface or the extracellular matrix, where the 
polysaccharide chains bind and regulate the activity of proteins (883 HS/heparin-
binding proteins identified to date
 [113, 114]
). Thus, a large body of evidence 
demonstrates the function of HSPGs in many signalling pathways. For example, 
mutations in the Drosophila of genes encoding sugarless (sgl) and sulfateless (sfl) 
have been shown to have similar phenotypes as Wingless (Wg) or Hedgehog (Hh) 
signalling mutants 
[115]
. In addition, the HS biosynthetic enzymes in Drosophila, 
Tout-velu (ttv), Sister of ttv (sotv) and brother of ttv (botv) are also required for Wg 
signalling gradient formation 
[116]
. Indeed, studies of morphogen activity have shown 
the function of HSPGs in regulation of morphogen movement and intercellular 
trafficking 
[117]
. A model of morphogen mobility suggests morphogen proteins can 
move from regions of high concentration to ones of low concentrations regions by 
transferal from one HSPG to the next in the pericellular matrix 
[118]
.  
HS regulates several aspects of FGF function. The interaction of paracrine FGFs 
with HS is absolutely required for the formation of an efficient signalling complex 
with the FGFRs. Thus, HS was shown to be required for FGF2 to stimulate cell 
division in heparan sulfate-deficient Chinese hamster ovary (CHO) cells 
[119]
. The 
same result was obtained by treating cells with heparitinase or culturing cells in 
sodium chlorate to block sulfation of heparan 
[120]
. However, experiments on 
overexpression of branchless in Drosophila suggested that FGFR can be activated by 
high levels of FGF in the absence of HS and biochemical signalling by FGF2 has 
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been measured in cell cultures in the absence of HS 
[121-123]
. Nonetheless, in all cases 
the usual paracrine FGF biological response (development of the trachea, cell 
division) required HS. Thus, the above work is also the first genetic evidence to 
show that HS is essential for normal FGF signalling in vivo 
[122]
. Additional studies 
have shown that the function of HS may be to stabilize the active receptor complex 
for enough time for it to signal 
[36]
. Moreover, structure defined oligosaccharides 
have also shown to differently activate FGFs, which indicates that different FGFs are 
likely to possess distinct affinities for unique HS structures 
[124, 125]
. 
The role of heparan sulfate intracellular has also been explored. Intracellular heparan 
sulfate was first identified in the nucleus of hepatoma cells 
[126]
. This HS was found 
to be enriched in 2-O sulfated glucuronic acid residues and to correlate with the 
control of cell growth and to originate from the extracellular space 
[126-128]
. Since, 
intracellular HS binding proteins have been identified. For example, the catalytic 
activity of topoisomerase I, which changes the superhelical state of duplex DNA, has 
been shown to be inhibited by interaction with heparan sulfate 
[129]
. Indeed, many 
nucleic acid binding proteins also bind heparin and presumably heparan sulfate. This 
is not surprising, since the sugar phosphate backbone of nucleic acids is analogous 
the sulfated glycosaminoglycans. Recently, the translocation of 3-O-sulfated heparan 
sulfate from the extracellular space to the neuronal cytoplasm has been shown, 
caused by the overexpression of 3OST2. This heparan sulfate binds to tau, which 
leads to the latter’s hyperphosphorylation, a molecular change that drives 
Alzheimer’s disease [130]. The intracellular presence of HS is established and some 
interactions demonstrated, such as that with tau. However, many of the interactions, 
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particularly with nucleic acid binding proteins have often only been demonstrated in 
vitro and whether they occur in the cell remains to be established. 
Other functions of HS are demonstrated by genetic diseases associated with 
mutations in the genes encoding some of the biosynthetic enzymes. The EXT1 and 
EXT2 genes, whose products catalyse the elongation of the HS chain, have been 
shown to be tumour suppressor genes. Thus, studies of sporadic and exostosis 
derived chondrosarcomas show that a loss of heterozygosity for chromosomes 8 and 
11 markers linked to EXT1 and EXT2 loci causes the disease 
[131, 132]
. Idiopathic 
hypogonadotropic hypogonadism (IHH) is associated with mutations in heparan 
sulfate 6-O-sulfotransferase 1 (HS6O1) and has been linked to idiopathic 
hypogonadotropic hypogonadism pathogenesis by both Kallmann syndrome 1 
(KAL1) -dependent and -independent mechanisms 
[133]
.    
 
1.6 FGF receptors 
1.6.1 FGF receptors 
The FGFRs are encoded by five fgfr genes, fgfr1-fgfr4 and fgfr-L1, which have been 
identified in humans, mice and zebrafish. Four of these receptors, fgfr1-fgfr4 encode 
tyrosine kinases (ca.800 amino acids) 
[31, 55]
. One and two fgfrs genes were identified 
in C. elegans (egl-15) and Drosophila (breathless and heartless), respectively. The 
receptor contains an extracellular region with three immunoglobulin domains (I, II, 
and III), a transmembrane helix, and a split intracellular tyrosine kinase domain (Fig. 
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1.6). The related fgfr gene, fgfr-L1 (also called FGFr5) lacks an intracellular tyrosine 
kinase domain.  
There are a large number of alternative RNA splicing events that generate different 
FGFR isoforms. The latter include two or three Ig loop isoforms that lack the D1 Ig 
domain and in some cases, e.g. Drosophila heartless, the gene only encodes this two 
Ig loop isoform 
[31]
. In mammals there are three different exons encoding the C-
terminal half of D3, Ig loop 3 in FGFR 1, 2 and 3. One, the “a” exon, encodes a 
secreted receptor extracellular domain while the “b” and “c” exons alter the sequence 
of D3 of the transmembrane receptor and provide a means to impact on ligand 
selectivity, such that the fgfr gene product can recognise preferentially different FGF 
ligand subfamilies 
[134, 135]
. Immunoglobulin domain I and the adjacent acid box have 
no independent FGF ligand binding activity, but play an important role in receptor 
auto-inhibition 
[136] 
and in binding an alternative set of ligands, the cadherins [137]. 
FGF ligands mainly interact with the immunoglobulin domains II, III and the linker 
region between II and III of the receptor 
[31]
. 
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Figure 1.6 FGFR domain structure. There are three immunoglobulin domains (I, 
II, and III). The heparin binding site is colored orange on domain II. The black box 
between domains I and II is the acid box. FGF binds to Ig II and most FGFs ligands 
interact with the adjacent surface of Ig III. The green region is the alternatively 
spliced second half of immunoglobulin domains III. TK = tyrosine kinase. 
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1.6.2 FGF signalling pathway 
The dimerisation of FGFR induced by engagement of the FGF ligand and HS co-
receptor allows the transphosphorylation of the activation loop of the intracellular 
tyrosine kinase domain. Subsequent transphosphorylations by the activated FGFR 
kinase occur on other tyrosine residues on the intracellular domain of the receptor 
that act as docking sites for the initiators of intracellular signalling pathways. In 
addition the FGFR kinase phosphorylates tyrosine residues on the adaptor protein 
fibroblast growth factor receptor substrate 2α (FRS2α) and on the phosphatase SHP2. 
FRS2 binds the juxtamembrane region of the FGFR and this interaction does not 
require phosphorylated tyrosine, while SHP2 binds to phosphorylated FRS2. The 
growth factor receptor-bound protein 2 (GRB2) binds to either phosphorylated 
tyrosines on the FGFR or on FRS2. The adaptor protein GRB2-associated binding 
protein 1 (GAB1), commonly associated with the hepatocyte growth factor/scatter 
factor receptor MET also bind to FRS2, and when phosphorylated on tyrosine 
residues by the FGFR acts as a further binding site for GRB2. The bound GRB2 in 
turn binds son of sevenless (SOS), which recruits RAS, leading to activation of 
mitogen-activated protein kinases (MAPK) via the kinases RAF and mitogen 
activated protein kinase kinase (MEK). GAB1 is essential for binding and activating 
phosphatidyl inositol 3 kinase (PI3K), which causes the downstream 
phosphorylation and activation of the AKT pathway. In terms of the signal outcome 
of the FGFR, the GRB2-MAPK pathway is associated with cell division, whereas 
the PI3K/AKT pathway is associated with cell survival and cell fate determination 
[138-140]
. Another well-established pathway is that of PLCγ, which binds directly to a 
phosphorylated tyrosine residue in the FGFR (tyr-766 in FGFR1). PLCγ is 
phosphorylated by FGFR kinase and then generates inositol triphosphate (IP3) and 
  
 
19 
diacyglycerol (DAG) by the hydrolysis of phosphatidylinositol, leading to the IP3-
mediated release of calcium from the endoplasmic reticulum. Calcium ions and DAG 
together cooperate to activate protein kinase C (PKC). Even though the physiological 
role of this pathway is not well elucidated, it has been shown to be involved in cell 
adhesion 
[141]
. 
The RAS-MAPK, PI3K and PLCγ pathways are the most studied and best described 
ones leading  from the activated FGFR.  These pathways cause changes in the 
activity of downstream kinases, phosphatases and proteins that result in the 
biological output of the FGF ligand. Generally, this is cell division or cell migration 
[140-143]
, but this may be a bias due to these being the most studied changes in cell 
behavior in the growth factor field.  
 
1.6.3 Specificity of FGF and FGFR interactions 
Except for FGF1, which interacts with all FGFRs and their isoforms, all other FGFs 
exhibit a greater or lesser degree of receptor and receptor isoform selectively (Table 
1.2). Although there is usually no absolute specificity (a notable exception is FGF7, 
Table 1.2), it is the case that FGFs from the same subfamilies have a clear preference 
to bind particular FGFR isoforms, whereas FGFs from different subfamilies differ in 
this respect (Table 1.2). The expression of at least some FGFR isoforms is tissue 
specific: for example, FGFR b isoforms are generally expressed in the epithelial 
compartments, while the FGFR c isoforms are normally produced in the 
mesenchymal tissue compartment. A general theme is that the FGFs expressed in 
epithelial or mesenchymal tissues interact with FGFR produced in the opposite tissue 
[55]
.  
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Table 1.2 FGFR binding specificities of FGFs.  Data from Ornitz et al. and Zhang 
et al. 
[35, 51]
. 
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1.7 Models for complexes of FGFs and their receptors 
There have been many studies aimed at establishing what the exact role of HS may 
be in the formation of signalling complexes with the FGFR. Although there is 
currently a consensus view on the role of HS, only some of the contradictory body of 
data has been resolved, a number of proposals exist to explain how the signalling 
complex is formed, and open questions remain.  
Based on the idea that the FGF ligand has to cause dimerisation of the FGFR to 
activate the tyrosine kinase, there are data indicating that binding of the FGF to HS 
causes dimerisation of the former. A dimeric ligand would enable receptor 
dimerisation. Heparin induced oligomerisation of FGF1 
[144]
 and cis dimers of FGF2 
was demonstrated on a heparin octasaccharide, but not on shorter structures such as a 
disaccharide or a tetrasaccharide
 [145, 146]
. This suggested that the specific side-by-side 
heparin-induced FGF2 dimer would be the minimal active structure required for its 
biological activity. In support of the dimersation model, an asymmetric 
crystallographic co-complex of 2:1:2 FGF1: heparin decasaccharide: FGFR complex 
has been proposed [147]. This ‘asymmetric’ model was formed by the dimerization of 
two FGF-FGFR complexes induced by heparin. Moreover, the decasaccharide 
interacts with both ligands in two 1:1 FGF1-FGFR2 complexes, but with just one of 
two receptors (Fig. 1.7B). In this and the symmetric model (see below) the atomic 
contacts between molecules are preserved, but the relative orientation of the 
receptors is quite different. Due to the lack of the contact between proteins, the role 
of heparin seems to be critical in the assembly of the ‘asymmetric’ complex [147]. 
Biophysical analysis was performed to validate the asymmetric model. This 
indicated a cooperative dimerisation of FGF1 on heparin derived oligosaccharides. 
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However, the dimerisation of FGFs on heparin and derived oligosaccharides requires 
a very high concentration of FGFs, where it is well established that the multivalency 
of the polysaccharide enables multiple FGFs to bind [148, 149]. 
An early biophysical analysis of FGF2 and FGFR1 using isothermal titration 
calorimetry, ultracentrifugation, molecular modeling and site-directed mutagenesis 
indicated that FGF2 binds to two receptors and one HS (FGF2: FGFR1: HS, 1:2:1) 
[150]. The affinity of FGF2 for FGFR1 was increased 10-fold by the presence of the 
heparin. In this model, the second FGFR1 was recruited to a secondary low affinity 
binding site on FGF2 with heparin stabilizing the complex (Fig. 1.7A). Since the 
second binding site of FGF2 has 250-fold lower affinity compared with the primary 
binding site mutation of the second binding site did not change measurable FGFR 
binding, but did cause a reduction of its mitogenic activity [151]. A similar effect was 
observed in FGF7 when point-mutations were proposed in the low affinity binding 
sites located loop between strands β9 and β10 [152]. This model, called “the growth 
hormone model” due to its mechanism being analogous to that of growth hormone, 
has since fallen out of favour, but there are as yet, no data to contradict it. One 
uncertainty, however, is whether some of the  residues contributing to the secondary 
FGFR binding site on the FGF2 are also involved in the packing of the hydrophobic 
core of the protein, hence the absence of mitogenic activity seen when these residues 
are mutated, which may be due to a loss of stability of the FGF2. 
The current consensus model is called the symmetric model and is based on data 
from co-crystals of a 2:2:2 complex of FGF2, a heparin-derived hexasaccharide and 
the extracellular Ig loops Ⅱ and Ⅲ of FGFR1, this is called the ‘symmetric’ model 
(Fig. 1.7C) (PDB ID 1FQ9) [112]. Primarily, the heparin oligosaccharide interacts with 
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FGF2 and FGFR1 to form a 1:1:1 complex. After that, dimerization of the two 
complexes is mediated by direct FGFR-FGFR interaction and secondary interaction 
between ligand in one ternary complex and receptor in the other ternary complex, 
with the FGF-FGFR interaction regulated by the sugar. It is important to note that 
these secondary contacts between FGF and FGFR are different from those in the 
growth hormone model. Since the non-reducing ends of both oligosaccharides face 
each other, this model was also called ‘two-end’ model [113]. The direct FGFR-FGFR 
and the secondary FGF-FGFR interaction were not sufficient for appreciable 
dimerization of the FGFR without the polysaccharide [112]. It is worth noting that, 
although the arrangements of the components differ in the symmetric and 
asymmetric models, the atomic contacts between FGF, heparin oligosaccharide and 
FGFR are very similar. Interestingly, in the symmetric model, the atomic contacts of 
the low affinity secondary FGFR binding site of FGF2 of the growth hormone model 
are free and exposed to solvent.  
There may be more than one functional complex. For example, Zhu et al. (2010), 
provided evidence for different signalling complexes forming on fibroblasts with 
FGF2 and the endogenous FGFR1 [121]. These different intracellular signals are 
identified due to differences in signalling observed for complexes of FGF2: FGFR1 
(no HS), FGF2: HS: FGFR1 and high FGF2 concentrations: HS: FGFR1. 
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Figure 1.7 Models of FGF signalling complexes. Heparin chains are coloured 
black. FGF is coloured green. For FGFR, only the Ig II (D2) and Ig III (D3) domains 
are shown, coloured in purple. A, the growth hormone model; B, the ‘asymmetric’ 
model; C, the ‘symmetric’ model. 
 
One fundamental difference between the ‘symmetric’ and ‘asymmetric’ model is the 
conformation of the invariant proline residue in the D2-D3 linker region. The 
invariant proline in the ‘symmetric’ model assumes a trans conformation, whereas 
the proline in the ‘asymmetric’ model is in cis. The cis and trans proline 
conformations were proposed to represent the active and inactive state of FGFR, 
respectively [147]. These two models have also been analysed in solution using size-
exclusion chromatography, analytical ultracentrifugation and mass spectrometry. 
This work suggests that both structures were present, but that the ‘asymmetric’ 
model complex predominates [153]. However, the FGFR with cis proline was used, so 
an alternative interpretation, given that the symmetric complex was detected, is that 
the latter is physiologically relevant. Moreover, the disruption of the low affinity 
FGFR binding site of FGF caused a reduction in cell signalling, which supported the 
‘symmetric’ model [154]. Analysis of the D2-D3 linker region in crystal structure 
1E0O has shown that the cis conformation of proline is stabilized by a large excess 
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of Ni2+ ions in the crystallization buffer, so pushing the equilibrium between these 
two proline conformations towards to cis, which supports the idea that this may be 
an artefact of expression and purification [155].  
 
 1.8 Specificity of FGF and HS interactions 
Heparan sulfate is a key regulator that controls the functions of a large number (883) 
of extracellular regulatory proteins 
[114, 156]
 (Section 1.5.3). FGFs are heparin-binding 
proteins and interactions with HS determine their transport between cells, as well as 
the assembly of signalling complexes with cognate FGFRs. In mammals, there are 
18 FGFs involved in mediating cell-cell communication by interaction with HS and 
FGFR on target cells (Section 1.3). In the fly Drosophila and the worm C. elegans, 
there are just two or three FGF ligands and one fgfr alongside HS (Section 1.2). It 
seems reasonable that to develop and maintain the more complex bodies of 
vertebrates and mammals, having 18 FGFs and 5 fgfrs with HS is necessary and has 
arisen by natural selection. In studies on binding of modified heparin fragments (all 
containing N-sulfate groups) to FGF1, FGF2 and FGF4, the results showed that 
FGF2 required 2-O-sulfate rather than 6-O-sulfate for binding. FGF1 was more 
promiscuous and could bind structures with either 2-O-sulfate or 6-O-sulfate and 
FGF4 could bind at high concentration oligosaccharides lacking 2-O-sulfate or 6-O-
sulfate [124, 125, 157]. Moreover, experiments are carried out in vivo have shown that 
FGFs clearly bind to different tissue compartments, e.g., in mammary gland FGF2 
was found to bind more extracellular matrix HS surrounding duct and less to the 
matrix surrounding the terminal end buds where the ductal tree is elongating and 
branching [158]. Moreover, differences have been observed in the effects of HS on the 
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growth-stimulatory effects of FGF1 and FGF2, for example in 3T3 cells [159].  
It remains the case, however, that the level of specificity for binding HS is still 
debated. One school, drawing on the perceived high specificity of the interaction of 
antithrombin III with a pentasaccharide in heparin, contends that there are rare and 
unusual sequences of saccharides in HS, and related heparin, responsible for high 
affinity binding of the proteins 
[160, 161]
. Another school contends that largely non-
specific ion-exchange interactions underpin protein binding by the polysaccharide 
[162, 163]
. After crystallographic analysis of the amino acid residues located in the 
binding region of heparin and FGFs, it was shown that no single residue in the 
primary canonical heparin binding site is completely conserved throughout the FGF 
family 
[40]
, indicating that there has either been genetic drift or natural selection. In 
early studies, an octasaccharide from heparin had been suggested to be the minimal 
length oligosaccharide to induce the assembly of FGF2-FGFR1/2 and its biological 
activities 
[125, 164, 165]
, though later heparin-derived tetrasaccharides were found to be 
functional 
[123]
. However, with oligosaccharides derived from HS, octasaccharides 
were the minimal active length 
[166]
. In contrast, the deduced dimerization of 
FGFR2b induced by FGF7 required heparin-induced oligosaccharides longer than dp 
8 
[167]
. Chemically modified heparins were used with FGF1 and FGF7 to show that 
FGF1-dependent dimerization of FGFR2b was enabled by 6-O- and 2-O-desulfated 
heparins, whereas neither of these polysaccharide could enable FGF1-FGFR1 or 
FGF7-FGFR2b to stimulate cell growth, which suggested that there may be a high 
degree of specificity in the formation of ligand-receptor complexes 
[167]
. In the most 
comprehensive work, FGFs from five subfamilies were characterized in terms of 
their heparin binding specificity at different levels: binding parameters, the heparin 
structure required for binding, the identification of the heparin binding sites in the 
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FGFs and the secondary structure changes induced by heparin binding. With most of 
the subfamilies represented by just one member, these data led to the hypothesis that 
the differences in the preference of individual FGFs for particular heparin structures 
and the type of secondary heparin binding site in the FGFs may be reflected in the 
evolutionary relationship of the different subfamilies 
[34]
.  
 
1.9 Aims 
FGFs often serve as a model for understanding the consequences of the interaction of 
HS with other proteins. Thus, the question of the specificity between FGFs and HS 
has wide implications. Previous work has not been very systematic, generally 
involving just one or two FGFs and a limited repertoire of GAG structures 
[124, 125, 162, 
168]
. The FGF family of growth factors has expanded into clearly defined subfamilies 
through a series of genome duplications and these have clear functional relationships 
e.g. Table 1.1. Thus, the FGF family can be used as a defined system, subjected to 
natural selection, to determine the level of specificity of interactions of FGFs with 
GAGs. The existing work with six FGFs from five subfamilies suggests that there is 
specificity in FGF- heparin interactions and this reflects the evolution of the FGF 
family members, which parallels the specificity of FGF ligands for FGFRs 
[34, 169]
. 
However, in this work only four of the five heparin binding FGF subfamilies was 
analysed and for three of these there was only one FGF represented. Thus, the idea 
that there is specificity in the interactions of FGFs with HS and that the 
polysaccharide binding properties of the FGFs have been subjected to the some 
selection pressure that led to their FGFR-binding specificities and functional 
specialization remains to be established. 
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A major aim of this thesis is to substantiate or otherwise the above hypothesis. To 
achieve this, at least two members of each paracrine subfamily have been produced 
to provide a far more comprehensive coverage of the FGF family. The specificity in 
their interactions of these FGFs with the polysaccharide has been determined in two 
ways. Firstly, the preferences of FGFs for particular sugar structures has been 
explored using differential scanning fluorimetry (DSF) and a library of chemically 
modified heparins, heparin derived oligosaccharides and model glycosaminoglycans. 
Secondly, the protect and label approach has been used to map primary and 
secondary heparin binding sites in the FGFs 
[170]
. The secondary heparin binding 
sites (HBS2 and HBS3) of FGF2 have also been characterized by exploring the sugar 
structure preference and the biological activity of HBS mutants. Finally, a new 
arginine targeted protect and label technique has been developed, which will be able 
to identify these residues, which make a substantial contribution to the ionic bonding 
capacity of HBSs. 
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Chapter 2 General materials and methods 
2.1 Electrophoresis 
2.1.1 Agarose electrophoresis 
Agarose gels (1.2 %, w/v) were made by melting agarose (0.4 g) (Bioline, London, 
UK) into 48 mL TAE buffer (40 mM Tris-Cl, 20 mM acetic acid, and 1 mM EDTA, 
pH 8). When the agarose had cooled slightly, 4 μL 10,000x SYBR (New England 
Biolab, UK) was added into the agarose. The molten agarose was poured into the gel 
making tray and allowed to cool. The samples and DNA ladder (1 kb New England 
Biolab, Herts, UK) were loaded on the gel after the gel tray was placed in the gel 
tank and covered with TAE buffer. Electrophoresis was carried out at 100 V, 30 min 
for each gel.    
2.1.2 SDS-PAGE 
Samples were analyzed by SDS-PAGE by mixing them with 1/5 volume of 5x SDS-
PAGE loading buffer (50 % (v/v) glycerol, 10 % (w/v) SDS, 25 % (v/v) 2-
mercaptoethanol in 0.3 mM Tris-Cl, pH 6.8 and coloured with bromophenol blue). 
Then, they were heated at 95°C for 3 min and centrifuged for 5 min at 12,000 x g. 
Typically, 10 µL sample and SDS-PAGE marker (SDS7-1VL, Sigma) were loaded 
onto a 12 % (w/v) SDS-polyacrylamide gel (Table 2.1) and the gels were run at 30 
mA (per gel), 200 V for 50 min with running buffer (50 mM Tris-Cl, 192 mM 
glycine and 0.1 % (w/v) SDS). 
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Table 2.1 SDS-PAGE 
Resolving Gel (ingredients for 12 % gel)                                              Total 10 mL  
       Acrylamide/ bis-acrylamide stock (30 %, w/v)                                      4.0 mL 
       Tris-HCl (3 M), pH 8.85                                                                         2.5 mL 
       Water                                                                                                       3.5 mL 
       10 % Sodium dodecyl sulphate (SDS) w/v                                             100 µL 
       TEMED (N, N, N’, N’, Tetramethylethylene diamine)                            10 µL 
        Ammonium persulphate 50 mg/mL (freshly made)                               100 µL 
Stacking Gel                                                                                          Total 10 mL  
       Acrylamide/ bis-acrylamide stock (30 %, w/v)                                       1.3 mL 
       Tris-Cl (1.25 M), pH 6.8                                                                             1 mL 
       Water                                                                                                        7.7 mL 
       10 % Sodium dodecyl sulphate (SDS) w/v                                              100 µL 
       TEMED                                                                                                      20 µL 
       Ammonium persulphate 50 mg/mL (freshly made)                                 100 µL 
 
2.1.3 Western Blot 
After separation of polypeptides on 12 % (w/v) SDS-polyacrylamide gels, the gels 
were packed against a PVDF membrane in a sandwich with pads. Proteins were 
transferred at 100 V for 60 min in transfer buffer (25 mM Tris-Cl, 192 mM glycine, 
20 % (v/v) ethanol). The membrane was then blocked with 5 % (w/v) skimmed milk 
powder in TBST (50 mM Tris-Cl, 150 mM NaCl, 0.05 % (v/v) Tween 20, pH 7.5) 
for 1 h. The membrane was washed three times with TBST to remove excess milk 
proteins and incubated overnight with phospho-p44/42
MAPK
 antibody (Cell signalling 
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Technology, Beverly, MA, USA) (1: 1000 dilution in TBST) on a shaker at 4°C. 
Following three washes with TBST, HRP-linked anti-rabbit IgG (Sigma, Gillingham, 
Dorset UK) (1: 5000 of a 1 mg/mL stock) was added to the membrane in TBST and 
incubated for 1 h at room temperature. After three washes with TBST, the membrane 
was covered with 1 mL ECL solution (GE Healthcare Life Sciences, 
Buckinghamshire, UK) and signal was detected with Hyperfilm (Fujifilm UK Ltd. 
Bedford, UK). The same membrane was re-blotted with anti-β-actin (Sigma, UK) as 
control after stripping with a solution containing 0.1 % (w/v) SDS, 1.5 % (w/v) 
glycine, and 1 % (v/v) Tween 20. The membrane was incubated twice with this 
solution at room temperature for 7 min, followed by washing twice with PBS (137 
mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L Na2HPO4 • 2 H2O, 2.0 mmol/L KH2PO4, 
pH 7.4). After two more washes with TBST, the membrane was ready for further 
incubations with antibodies.   
2.1.4 Coomassie Staining and Destaining 
The gels were incubated in Coomassie stain (50 % (v/v) methanol v/v, 10 % (v/v) 
acetic acid, 0.25 % (w/v) CBB R-250) for 60 min, then soaked in de-staining buffer 
(30 % (v/v) methanol, 10 % (v/v) acidic acid) until the bands became clear. 
2.1.5 Silver staining 
After electrophoresis, the gels were soaked in fixative (40 % (v/v) ethanol, 10 % (v/v) 
acetic acid) for 1 hour. Then, the gels were rinsed twice in 10 % (v/v) ethanol for 5 
min and washed in water three times for 5 min each. The gels were then incubated in 
0.02 % (v/v) silver nitrate solution for 30 min. After rinsing in water for 5 s, the gels 
were washed once in freshly made developer solution (2.5 % (w/v) Na2CO3, 0.03 % 
(v/v) formaldehyde) until the solution went brown. The gels were transferred to fresh 
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developer buffer and left on a shaker until bands were stained to the required 
intensity. Stop solution (1 % acetic acid) was used to terminate staining and gels 
were then washed with water six times for 5 min each. The gels were rinsed with 
freshly made reducer (0.6 % sodium thiosulphate, 0.3 % potassium ferricyanide, 0.1 % 
sodium carbonate) until the background became clear. Then the gels were quickly 
washed in a large volume of water to remove the reducing buffer. Finally, the gels 
were washed five times for 5 min each with water. 
 
2.2 cDNA cloning 
2.2.1 Polymerase chain reaction (PCR) 
PCR was used to amplify cDNAs in 50 µL reactions, the reaction mixture and PCR 
cycle settings are shown in Table 2.2. 
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Table 2.2 PCR reaction setting 
A, PCR reaction mixtures 
Mixture                                                                                                   Volume 
Hot start polymerase buffer                                                                      5 µL 
25 mM MgCl2                                                                                           3 µL 
dNTPs                                                                                                       5 µL 
PCR Grade Water                                                                                   31 µL 
Forward Primers                                                                                       2 µL 
Reverse Primers                                                                                        2 µL 
DNA template                                                                                           1 µL  
Hot start polymerases (New England Biolabs)                                         1 µL 
Total                                                                                                         50 µL 
B, PCR cycles 
                                         Stage1                     Stage2                          Stage3 
Temperature (°C)               98                     95         Tm      70             70       4 
Time (s)                            120                    20         10        20             600      ∞ 
Cycles                                1                      30         30        30               1     Finish 
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2.2.2 DNA digestion 
The target DNA was digested by two corresponding enzymes at 37°C overnight. The 
ligation mixture is shown in Table 2.3. 
Table 2.3 Digestion system 
Mixture                                                                                                      volume                                                                                                      
DNA                                                                                                             5 µL 
NE Buffer                                                                                                     2 µL     
Water                                                                                                            1 µL  
NcoI-HF (New England Biolabs)                                                                1 µL 
BamHI-HF (New England Biolabs)                                                           1 µL  
Total                                                                                                           10 µL 
 
2.2.3 Ligation 
The insert and vector plasmid were ligated by T4 ligase (M0202L, New England 
Biolads, UK) at room temperature overnight. The ligation condition is shown in 
Table 2.4. 
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Table 2.4 Ligation system 
Mixture                                                                                                       volume 
Vector                                                                                                         3.5 µL 
Insert                                                                                                           3.5 µL 
T4 ligase buffer                                                                                             2 µL 
T4 ligase                                                                                                        1 µL  
Total                                                                                                            10 µL 
 
2.2.4 Mutagenesis  
The target fragments were designed by site-mutation of sequence of FGF2 and 
bought from Life Technologies. Target fragments amplified by PCR with designed 
primers were digested with NcoI-HF and BamHI-HF to produce the fragment to be 
ligated with the vector, digested with the same enzymes. The ligated sample was 
transformed into DH5 alpha cells and then large-scale cultures were used for 
isolation of the target plasmid.  
 
2.3 Protein expression 
2.3.1 Materials 
Lysogeny Broth (LB) culture medium (Merck, Watford, UK). 
2xYT culture medium: 1.6 % (w/v) enzymatic digest of casein, 1.0 % (w/v) yeast 
extract, 0.5 % (w/v) NaCl, pH: 7.2.  
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Terrific Broth (TB) medium: 1.2 % (w/v) tryptone, 2.4 % (w/v) yeast extract, 0.4 % 
(v/v) glycerol, 0.17 M KH2PO4, 0.72 M K2HPO4. 
2.3.2 Competent cell preparation 
A single colony of selected bacteria (DH5 alpha/C41/BL21 (DE3)) was cultured in 
40 mL of LB broth overnight at 37°C until the absorbance reached 0.3-0.5. The 
culture were immersed in ice for 10 min and transferred to 4 pre-chilled sterile 
centrifuge tubes and then centrifuged at 3800 x g for 10 min, 4°C. The pellets were 
placed on ice for 10 min and re-suspended in 10 mL pre-chilled 0.1 M CaCl2. These 
samples were placed on ice for a further 20 min, and then centrifuged, as above. 
Finally, pellets were re-suspended in 2 mL 0.1 M CaCl2. Competent cells were 
stored at -80°C. 
2.3.3 Bacterial transformation 
Seventy ng pETM-11 DNA and 70 µL competent C41 (DE3) or BL21 (DE3) plysS 
were thawed on ice. They were then mixed together and incubated on ice for 30 min. 
After a process of permeabilization induced by heat shock at 42°C for 1 min and 
incubation for 2 min on ice, cells were added to 1 mL LB and cultured at 37°C for 60 
min. The cells were collected by centrifugation (3800 x g) for 5 min and re-
suspended with 100 µL of LB and 10-25 µL of the cell suspension was plated into 
LB-antibiotic (Ampicillin/Kanamycin) plates. These plates were incubated at 37°C 
overnight. 
2.3.4 Miniprep 
A single colony from the plates was inoculated and cultured with 10 mL of LB 
broth-antibiotics at 37°C overnight ( shaken at 240 rpm). Plasmids were purified 
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using a Qiagen miniprep kit 250 according to the manufacturer’s instruction (Qiagen, 
Manchester, UK). 
2.3.5 Sequencing 
Plasmid DNAs (80-100 ng/µL) were sequenced by GATC sequence service (GATC, 
UK). 
2.3.6 Bacterial culture 
A single colony was inoculated and cultured with 10 mL of LB/ 2xYT broth-
antibiotic at 37°C overnight (shaken at 240 rpm). Five ml of this culture was 
transferred to 500 mL of LB/ 2xYT broth with antibiotic and then cultured at 37°C 
with shaking (240 rpm) until the absorbance at 600 nm reached 0.5-0.9. At this point, 
the cultures were induced with IPTG (1 mM final concentration) and grown at 37°C 
(240 rpm) for 3 h, or overnight at 19.5°C (180 rpm). The bacteria were transferred to 
pre-cooled 1 L centrifuge tubes and centrifuged for 15 min at 4,150 x g. The cell 
pellets were re-suspended in PBS and transferred to 50 mL tubes. The cells were 
then centrifuged again for 10 min at 3,800 x g. The supernatants were discarded and 
pellets were stored at -80°C. 
 
2.4 Protein purification 
2.4.1 Cell breakage 
Samples were thawed on ice with 5 volumes of lysis buffer (equilibration buffer for 
the subsequent chromatography step) and transferred to a 50 mL glass beaker for 
sonication. Cells were disrupted by six 30 s cycles of sonication, each for 1 min on 
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ice.  Broken cells were centrifuged again in pre-chilled 50 ml centrifuge tubes at 
38000 x g for 30 min. The supernatant was then used for the isolation of protein. 
2.4.2 Chromatography 
2.4.2.1 Heparin affinity chromatography 
A column with 3 mL heparin resin (Affi-Gel Heparin, BioRad, UK) was equilibrated 
with buffer (50 mM Tris-Cl, 0.4 M NaCl, pH 7.2) at a flow rate of 1 mL/min. After 
cell breakage, the supernatant was filtered through a 0.45 µM filter and applied to 
the column. The column was then washed with washing buffer Ah (50 mM Tris-Cl, 
0.4 M NaCl, pH 7.2) and washing buffer Bh (50 mM Tris-Cl, 0.6 M NaCl, pH 7.2). 
Elution was achieved by high ionic strength elution buffers Ch (50 mM Tris-Cl, 1.0 
M NaCl, pH 7.2) followed by  Dh (50 mM Tris-Cl, 1.5 M NaCl, pH 7.2). The 
column effluent was monitored at 280 nM with an Econo UV monitor (Bio-rad, 
Hertfordshire, UK). 
2.4.2.2 Nickel affinity chromatography 
A column of ProBond nickel-chelating resin (Invitrogen, Paisley, Scotland, U.K.) 
was equilibrated with equilibration buffer (50 mM Tris-Cl, 0.02 M imidazole, 0.3 M 
NaCl, pH 7.0). Then, the supernatant of disrupted cells was loaded onto this column 
and washed with washing buffer An (50 mM Tris-Cl, 0.02 M imidazole, 0.3 M NaCl, 
pH 7.2) and then washing buffer Bn (50 mM Tris-Cl, 0.1 M imidazole, 0.3 M NaCl, 
pH 7.2) at a flow rate of 1 ml/min. A higher concentration of imidazole was used in 
the elution buffers Cn (50 mM Tris-Cl, 0.25 M imidazole, 0.3 M NaCl, pH 7.2) and 
Dn (50 mM Tris-Cl, 1.0 M imidazole, pH 7.2). The column effluent was monitored 
at 280nm with a Bio-Rad (Hemel Hempstead, UK) Econo UV Monitor.  
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2.4.2.3 Cation-exchange chromatography 
The fractions from heparin affinity chromatography were diluted 6 fold with buffer 
AI (50 mM Tris-Cl, pH 7.2) and applied to a cation-exchange column (1 mL HiTrap 
SP HP) set up on an AKTA system (GE Healthcare). Proteins were eluted with a 0-1 
M NaCl gradient in 50 mM Tris-Cl, pH 7.2. The flow rate was 0.5 mL/min and 
elution was monitored at 280 nm. 
 
2.5 Mammalian cell culture 
2.5.1 Cell lines 
Rama (rat mammary) 27 fibroblast cells 
2.5.2 Tissue culture reagents 
BSA (bovine serum, albumin) (Sigma-Aldrich); Trypsin/EDTA solution: 25 mL 
versene (Life Technologies) containing 2.5 % trypsin (in PBS, w/v); PBS (phosphate 
buffered saline): 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 Mm KH2PO4, 
pH 7.2; RM (Routine medium): DMEM (Dulbecco’s modified Eagle’s medium) 1 × 
(Gibco Life Technologies), 10 % (v/v) FBS (foetal bovine serum), 0.75 % sodium 
bicarbonate (Invitrogen, Paisley, UK), 20 mM L-glucosamine (Gibco), 1.00 IU/mL, 
penicillin (Gibco), 100 μg/mL streptomycin (Gibco), 50 ng/mL insulin (Sigma-
Aldrich), 50 ng/mL hydrocortisome (Sigma-Approach); SDM medium (step down 
medium): DMEM, 0.75 % sodium bicarbonate, 20 mM L-glucosamine (Gibco), 1.00 
IU/mL, penicillin (Gibco), 100 μg/mL streptomycin (Gibco), 250 µg/mL BSA 
(Sigma, catalogue number 7030); Freezing medium: 7.5 % (v/v) DMSO (Dimethyl 
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sulphoxide) and 20 % (v/v) FBS in DMEM; Tissue culture Petri dishes (Nunc, 
Roskilde, Denmark).  
2.5.3 Cell culture 
Rama (rat mammary) 27 fibroblast cells were thawed at 37°C and transferred to a 25 
mL universal tube. Twenty mL DMEM (with 20 % (v/v) FBS) was added slowly 
into the universal tube and then the cells were centrifuged at 800 rpm for 5 min. The 
supernatant was removed and the pellet was re-suspended in 10 mL pre-warmed RM 
and all of cells were then placed into culture dishes and incubated at 37°C. 
The cells were cultured with RM at 37°C in 9 cm diameter dishes in a humidified 
atmosphere of 10 % carbon dioxide and 90 % air (both v/v). The cells were sub-
cultured at a ratio of 1:8 when the density of cells reached 70 % confluence. Cells 
were washed with PBS twice and then detached by incubating in 1 ml Versene at 
37°C for 1 min. Seven mL RM was applied to re-suspended detached cells and then 
1 mL was transferred to new culture dish. To retain their growth characteristics, the 
passage range of cells used was between 30 and 40. 
2.5.4 Cell counting 
 Detached cells (0.5 mL) were diluted to 20 mL with Coulter Isoton II diluent 
(Beckman Coulter). The cells were counted in a Coulter Electronics particle counter. 
Cells from each dish were counted three times. 
2.5.5 Freezing cells  
Detached cells were transferred to a universal tube and centrifuged at 120 x g for 5 
min. After removing the supernatant, the cell pellet was resuspended with 1 mL RM 
medium and then stored in 1.5 mL cryotube at -80°C. 
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2.6 Identification of proteins using peptide mass 
fingerprinting  
Gel slices from SDS-PAGE were washed with 50 % acetonitrile, 0.2 M ammonium 
bicarbonate pH 8.9 and then dried in a rotary evaporator. The slices were re-swollen 
in rehydration buffer (0.2 M ammonium bicarbonate pH 7.8, 2 M urea) containing 
trypsin and incubated at 37°C overnight. Peptides were extracted from the gel slices 
with 60 % (v/v) acetonitrile, 0.1 % (w/v) TFA, de-salted using Millipore C18 
ZipTips (Merck, Watford, UK). The latter were pre-wetted with 100 % (v/v) 
acetonitrile (ACN) and then pre-equilibrated with 0.1 % (w/v) TFA. They were 
loaded on the Zip Tip and then washed with 10 µL 0.1 % (W/v) TFA. Finally, these 
peptides were eluted with 2 aliquots of 4-6 µL 50 % (v/v) CAN. The peptides were 
then subjected to MALDI-TOF (Waters Corp., Manchester, UK) analysis using 
hydrocinnamic acid as the matrix. 
 
2.7 Size exclusion chromatography-multi-angle laser light 
scattering (SEC-MALLS) 
Analysis of the solution molecular mass were performed by separation of proteins on 
Superose 200 HR10/300 columns (GE Healthcare) connected in series with a Wyatt 
Dawn8
+
 and Wyatt Optilab T-rEX (Wyatt Technology) at 22°C. Samples (100 µL) 
were filtered and then applied to the column, which was developed in 150 mM NaCl 
buffer with either 50 mM HEPES or 50 mM Tris-Cl, both pH 7.4 at a flow rate of 
0.75 mL/min. 
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2.8 Differential Scanning Fluorimetry (DSF) 
The sugar structure required for binding to FGFs was measured by DSF. It was 
performed with a 7500 Fast Real Time PCR (RT-PCR) system (software version 
1.4.0 Applied Biosystems, Life Technologies, Paisley, UK). The melting 
temperatures (Tm) of a variety of FGFs (at 5 µM) were determined in the presence 
of various sugars. Heparin (0-500 µM), heparin-derived oligosaccharides of degree 
of polymerisation (dp) 2 to 12, chemically modified derivatives D1-D9 (Fig 4 B), 
porcine mucosal heparin sulphate, HA, CS, DS, and cation modified heparins were 
used as 10-fold concentrated stock solution (1.75 mg/ml) in HPLC grade water. First 
of all, protein stock solution (3.5 µL), heparin derivatives (3.5 µL), phosphate-
buffered saline (24.5 µL), and freshly prepared 100-fold stock solution Sypro Orange 
dye (3.5 µL) were added to a Fast Optical 96 Well Reaction plate (Applied 
Biosystems) maintained on ice. After sealing with Optical Adhesive Film (Applied 
Biosystems), the plate was directly analysed in the RT-PCR system. The heating 
cycle was performed as a gradient between 32 and 81°C in 99 steps of 20 s. First 
derivatives of the melting curves were calculated with Origin 7 (OriginLab Corp., 
Northampton, UK). For each heparin derivative, at least two experiments each with 
triplicate wells were performed and analyzed. The mean Tm and the standard error 
(S.E.) were calculated based on the six repeats. The formula used to normalized data 
was: Tm x-Tm PBS /Tm hep- Tm PBS, where Tm x is the Tm of protein in the 
presence of the heparin derivative; Tm PBS (or Tm Tris) is the Tm of protein itself, 
and Tm hep is the  mean Tm of the protein in the presence of heparin. The relative 
stability of protein in PBS or Tris-Cl buffer was set to 0, while the relative stability 
of heparin was set to 1. 
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2.9 Identification of heparin binding sites by Protect and 
Label 
2.9.1 Protection labelling on heparin 
A heparin minicolumn was made by placing a plastic air filter at the end of P10 tip 
(P50) into which 30 µL AF—heparin beads (Tosoh Biosciences GmbH, Stuttgart, 
Germany; binding capacity of 4 mg ATIII/mL) was packed. A 5 mL syringe was 
used to pack the minicolumn and dispense buffer. The heparin column was 
equilibrated 4 times with 50 µL of PB 150 buffer (17.9 mM Na2HPO4, 2.1 mM 
NaH2PO4, 150 mM NaCl, pH 7.8). A minimum of 40 µg FGF protein was loaded 
onto the heparin column and the loading was repeated 3 times with the same sample. 
After binding, the column was washed with PB 150 buffer 4 times. To acetylate 
exposed lysines, the minicolumn was then quickly rinsed with 20 µL of PB 150 
containing 50 mM sulfo-NHS-acetate and then incubated for 5 min with 20 µL of PB 
150 containing 50 mM fresh sulfo-NHS-acetate at room temperature. After 
acetylation, the minicolumn was washed with 50 µL of PB 150 buffer and acetylated 
protein was eluted with 2 x 20 µL elution buffer (45 mM Na2HPO4, 5 mM NaH2PO4, 
2 M NaCl, pH 7.8). 
 2.9.2 HBS Lysine Biotinylation 
Acetylated protein was diluted with 200 µL of PB buffer (17.9 mM Na2HPO4, 2.1 
mM NaH2PO4, pH 7.8) and concentrated with a 5 kDa-MWCO centrifugal filter 
(Sartorius Ltd., Epsom, UK) about 15 min at 9,000 x g. The volume was adjusted to 
37.2 µL with PB buffer and the biotinylation was performed by the addition of 2.8 
µL of 145 mM NHS-biotin in DMSO and a 30 min incubation at room temperature. 
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The biotinylation reaction was quenched with 4 µL of 1 M Tris-Cl, pH7.5. Then, the 
reaction was transferred to a desalting centrifugal column and covered with 70 µL 
HPLC grade water. After 2 minutes centrifugation at 1,200 x g, samples were stored 
at -80°C for 10 min and dried by centrifugal evaporation.  
2.9.3 Protein Digestion 
Dried sample was dissolved in 25 µL of 8 M urea, 400 mM NH4HCO3, pH 7.8 and 
2.5 µL of 45 mM DTT and incubated for 15 min at 56°C. Then, the samples were 
carbamidomethylated in the dark with 2.5 µL of freshly made 0.1 M iodoacetamide 
for 15 min at room temperature. Proteins were diluted with 70 µL of HPLC grade 
water and digested overnight with 1µg of chymotrypsin. 
2.9.4 Biotinylated Peptide Purification 
A minicolumn was made by placing a plastic air filter at the end of P10 tip (P50). 
Then, forty µL Strep-Tactin Sepharose beads (IBA-Solutions for Life Sciences, Life 
Technologies, Paisley, UK) were packed in this column. It was then rinsed 4 times 
with 50 µL 500 mM urea, 25 mM NH4HCO3. Digested protein was diluted to a final 
volume of 400 µL with HPLC grade water. The sample was then loaded onto the 
minicolumn and re-cycled through three times to ensure efficient binding. The 
column was washed 3 times with 50 µL 500 mM urea, 25 mM NH4HCO3 and then 
washed twice with 50 µL HPLC water to remove unbound peptides. Biotinylated 
peptides were eluted with 20 µL 80 % (v/v) ACN, 20 % (v/v) TFA and 5 mM biotin.  
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2.9.5 Identification of Labelled Peptides 
Biotinylated/acetylated peptides were made up to 0.5 % (w/v) TFA and desalted 
using C18 Zip Tips as in section 2.7. The samples were concentrated by rotary 
evaporation and analyzed by MALDI-TOF mass spectrometry. 
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Chapter 3 Expression, purification and 
characterisation of recombinant FGFs 
3.1 Subcloning of FGF cDNAs 
3.1.1 Materials 
cDNA-cDNA encoding human FGF-4 (UniProt accession number P08620; residues 
31-206) and FGF2 mutants HBS2 (208K/A, 219K/A, 249R/A, 251R/A, 252K/A) 
and HBS3 (160K/A, 163K/A, 164R/A)  (all from Life Technologies) were inserted 
into vector pETM-11 (a kind of gift from Dr Paul Elliott, University of Liverpool, 
UK). pET-14b-FGF-2, pETM-11-FGF-3, pETM-11-FGF-7, pETM-11-FGF-16 and 
pET-14b(halo)-FGF-17, were prepared as described 
[171]
.   
Table 3.1 Primers designed for amplifying FGFs. 
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3.1.2 Methods 
3.1.2.1 Production of FGF4 cDNA and the FGF-2 mutant cDNA 
A cDNA encoding FGF4 with two flanking cleavage sites (NcoI, CCATGG and 
BamHI, GGATCC) was designed and expression was optimized by Life 
Technologies through reduction of mRNA secondary structure and adapting the 
DNA sequence to E. coli codon usage as far as possible. Two FGF2 mutants were 
similarly designed and optimized lysine and arginine residues of heparin binding 
sites were replaced with alanine. Depending on which heparin binding site was 
mutated, the mutants were named as FGF2 (HBS2) and FGF2 (HBS3). 
3.1.2.2 Ligation 
The cDNA fragments of FGF4 and of the FGF2 mutants were digested with NcoI-
HF and BAMHI-HF to produce the insert which was then ligated with digested 
pETM-11 vector (Fig. 3.1, Section 2.22 and 2.2.3). The ligation product was 
transformed into DH5 alpha. All ligation products were sequenced to ensure they 
were identical to the designed DNA sequences.  
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Figures 3.1 Expression of plasmid map of FGF4 and FGF2 mutants. FGF4 (534 
bp) and FGF2 mutants (546 bp) (Red) were ligated into pETM-11, which contain a 
6xhistag and a TEV-site. 
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3.2 Paper: HaloTag is an effective expression and 
solubilisation fusion partner for a range of fibroblast 
growth factors 
Changye Sun, Yong Li, Sarah E Taylor, Xianqing Mao, Mark C. Wilkinson, David 
G. Fernig. (2015). HaloTag is an effective expression and solubilisation fusion 
partner for a range of fibroblast growth factors. PeerJ 3:e1060; DOI 
10.7717/peerj.1060. 
Contributions 
Yong Li: The cloning of cDNA of Histag-FGF3, Histag-FGF7, Halotag/Histag-
FGF16 and Halotag/Histag-17. Expression and Production of FGFs. Assisted with 
biological activities assay. Data analysis. Co-wrote the paper. 
 
This paper has shown the process of DNA cloning, protein expression and 
purification of Histag-FGF3, Histag-FGF7, Halotag/Histag-FGF16 and 
Halotag/Histag-17. The following sections are supplementary data showing the 
process on FGF2, His-FGF2 mutants and His-FGF4. 
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3.3 Supplemental results of expressions and purification of 
FGFs 
3.3.1 Bacteria transformation 
Seventy ng of pET-14b-FGF-2, pET-14b-FGF-2 (mutants), pETM-11-FGF-3, 
pETM-11-FGF-4, pETM-11-FGF-16 were transformed into C41 (DE3) cell, while 
pETM-11-FGF-7 and pET-14b (halo)-FGF-17 were transformed into 70 µL BL21 
(DE3) plysS cells (Section 2.3.3). 
3.3.2 Bacterial cultures 
3.3.2.1 His-tagged FGF3, His-tagged FGF7 and His-tagged FGF16  
C41 cells containing FGF2 mutants and BL21 cells containing His-tagged FGF3, 
His-tagged FGF7 or His-tagged FGF16 were cultured into 3 L (6x 500 mL) LB broth 
with kanamycin (50 mg/mL) and induced overnight with IPTG (1 mM) at 16°C (180 
rpm) (section 2.4.6).  
3.3.2.2 FGF-2 and its mutants 
C41 cells containing FGF-2 and its mutants were cultured in 3 L (6x 500 mL) LB 
broth- ampicillin (10 mg/mL) and induced with IPTG (1 mM) at 37°C (240 rpm) for 
3 h or at16°C (Mutants) (180 rpm) overnight (section 2.4.6). 
3.3.2.3 His-tagged FGF4 
C41 cells containing His-tagged FGF4 were cultured in 3 L (6x 500 mL) 2x YT 
medium- kanamycin and induced with IPTG (1 mM) at 37°C (240 rpm) for 3 h 
(section 2.4.6). 
  
 
75 
3.3.3 Results of purification of FGFs 
The purification of His-tagged FGF3, His-tagged FGF7, His-tagged FGF16 and 
Halo-tagged FGF-17 has been described in Section 3.2. The purification of FGF4, 
FGF2 and its mutants is described below. In all cases, cells were collected, lysed and 
the soluble proteins were isolated by centrifugation as described in 
[171]
. 
3.3.3.1 FGF2 
After cell breakage and centrifugation, the supernatant was loaded onto a 1 mL Hi-
Trap heparin column and eluted with buffer (50 mM Tris-Cl, 1.0 M NaCl, pH 7.2). 
Some contaminants were apparent in the eluate (Fig. 3.2), however, so further 
purification was required. The eluate was diluted 6-fold with buffer (50 mM Tris-
HCl, pH 7.2) and applied to a 1 mL HiTrap SP HP cation-exchange column, which 
was then developed with a gradient of 150 mM to 1 M NaCl, both in 50 mM Tris-Cl, 
pH 7.2). The fractions containing pure FGF2 (Fig. 3.2) were stored at -80°C. 
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Figure 3.2 SDS PAGE of different stage of FGF2 purification (Mw≈ 16.7 kDa).  
A 3 L culture was collected by centrifugation, disrupted by sonication and cell debris 
removed by further centrifugation. The soluble proteins were applied onto a 1 mL 
Hi-Trap Heparin column. The 1 M NaCl eluate was diluted 6-fold and then applied 
to 1 mL Hi-Trap SP HP cation-exchange column. The fraction containing FGF2 was 
eluted with 50 mM Tris-HCl in 1 M NaCl, pH 7.2. ‘Pellet’, - insoluble part of 
sample following centrifugation of disrupted bacteria; ‘Supernatant’, - soluble part of 
disrupted bacteria; ‘FT’, - unbound material during sample loading and buffer 
washing of the Hi-Trap heparin column; ‘1 M’, - elution with 1 M NaCl in 50 mM 
Tris buffer pH 7.2; ‘Ion-exchange chromatography’, - the fractions eluted from Hi-
Trap SP HP column. 
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3.3.3.2 FGF2 mutant (HBS2) 
The expression and purification of FGF2 (HBS2) was performed similarly to that of 
FGF2. After cell breakage, the supernatants were loaded on a heparin affinity 
column. However, FGF2 (HBS2) did not elute in 1 M NaCl but instead was found to 
elute in 1.5 M NaCl, 50 mM Tris-Cl, pH 7.2 (Fig. 3.3A). The eluant from the heparin 
affinity chromatography was diluted to less than 150 mM NaCl with 50 mM Tris-Cl, 
pH 7.2 and then applied to and eluted from a cation-exchange column, exactly as for 
FGF2 (Fig. 3.3B). Two bands highlighted by black arrow and red arrow on gel were 
cut and digested with trypsin. The digested peptides were applied to MALDI-Q-TOF 
and identified as part of FGF2 (HBS2) (data not shown). These two bands could be 
FGF2 (HBS2) with or without histag. 
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Figure 3.3 SDS PAGE of samples containing FGF2 (HBS2) (Mw≈ 18.7 kDa).  
Sample of disrupted bacteria was applied to a 1 mL Hi-Trap heparin HP column. The 
1 M NaCl eluate was diluted 6-fold with 50 mM Tris, pH 7.2 and then applied to a 1 
mL Hi-Trap SP HP cation-exchange column. The fraction containing FGF2 (HBS2) 
was eluted with 50 mM Tris-Cl, 1 M NaCl, pH 7.2. A, heparin affinity 
chromatography, ‘Pellet’, - insoluble part of sample followed by centrifugation of 
disrupted bacteria; ‘Supernatant’, - soluble part of disrupted bacteria; ‘FT’, - flow 
through and wash fractions from the heparin-affinity column; ‘1 M’, - fractions 
eluted with 1 M NaCl, 50 mM Tris, pH 7.2; B, ‘cation-exchange chromatography’, - 
the eluate from Hi-Trap SP HP column.  
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3.3.3.3 FGF2 mutant (HBS3) 
Following cell breakage, the supernatant was applied to a 1 mL Hi-Trap heparin HP 
column and washed with buffer Bh (50 mM Tris-Cl, 0.6 M NaCl, pH 7.2). The 
fraction containing FGF2 (HBS3) was eluted with elution buffer Ch (50 mM Tris-Cl, 
1.0 M NaCl, pH 7.2) (Fig 3.4).  
 
Figure 3.4 SDS PAGE of samples containing FGF2 (HBS3) (Mw≈ 21 kDa).  
A 3 L culture was disrupted by sonication and the soluble part was subjected to 
heparin-affinity chromatography. The fraction contained FGF2 (HBS3) was eluted 
with 1 M NaCl, 50 mM Tris-HCl, pH 7.2. ‘Pellet’, - insoluble part of sample 
followed by centrifugation of disrupted bacteria; ‘Supernatant’, - soluble part of 
disrupted bacteria; ‘FT’, - fractions came from column during sample loading and 
buffer washing; ‘0.6 M’, - fraction eluted with Tris buffer contained 0.6 M NaCl; ‘1 
M’, - fractions eluted with Tris buffer contained 1 M NaCl. 
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3.3.3.4 FGF4 
Following cell breakage, the supernatant was applied to a 1 mL Hi-Trap heparin HP 
column, washed with buffer (0.6 M NaCl in 50 mM Tris-Cl, pH 7.2.), then eluted 
with buffer (1 M NaCl in 50 mM Tris-Cl, pH 7.2). To remove the contaminants in 
the fraction eluted from heparin (Fig. 3.5A), cation-exchange chromatography was 
used. The fraction was diluted 6-fold with buffer (50 mM Tris-Cl, pH 7.2) and 
applied to a 1 mL Hi-Trap SP HP column. The column was then mounted onto an 
AKTA system and eluted with a gradient of 0.15 M to 1 M NaCl in 50 Tris-Cl, pH 
7.2 (Fig. 3.5B). The fractions containing pure FGF4 were stored at -80°C. 
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Figure 3.5 SDS PAGE of different stage of FGF4 purification (Mw≈ 13.7 kDa).  
A 3 L culture was disrupted by sonication and the soluble part of disrupted bacteria 
was applied to a 1 mL Hi-Trap Heparin column. The 1 M NaCl eluate was diluted 6-
fold and then applied to a 1 mL Hi-Trap SP HP column. The fraction containing 
FGF4 was eluted with a gradient of NaCl. A, ‘Pellet’, - insoluble part of sample 
following centrifugation of disrupted bacteria; ‘Supernatant’, - soluble part of 
disrupted bacteria; ‘FT’, - flow through fractions during sample loading and buffer 
wash; ‘1 M’, - fractions eluted with 1 M NaCl in 50 mM Tris, pH 7.2; B, ‘cation-
exchange chromatography’, - the fractions eluted from the Hi-Trap SP HP column. 
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3.4 Size exclusion chromatography-multi-angle laser light 
scattering (SEC-MALLS) 
SEC-MALLS was used to determine an accurate measurement of the molar mass of 
FGFs and whether the FGFs existed as monomers or oligomers.  
After purification, FGF2, Histag-FGF2 mutants (HBS2, HBS3), Histag-FGF4, 
Halotag-FGF6, Histag-FGF10, FGF-17, and Histag-FGF20 were loaded onto the  
SEC-MALLS system and analysed using the on-board ASTRA software (version 
6.1). The stability and accuracy of the system were first measured with a 50 µg 
bovine serum albumin standard. Afterwards, at least 50 µg FGF2 was analysed and 
its molecular weight and differential reflective index were obtained (Fig. 3.6A). The 
single peak and molecular mass (17.6 kDa) indicated that FGF2 existed as monomer. 
However, with FGF20 the molecular mass (39.8 kDa) was double that expected of a 
FGF20 monomer, which suggested that FGF20 is dimer (Fig. 3.6B). Since only one 
peak appeared during the measurement, this indicated that FGF20 exists as dimer 
and that no monomer-dimer equilibrium was apparent under these conditions (Fig. 
3.6B). 
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Figure 3.6 The average molecular mass per volume unit volume and the 
differential refractive index of FGF2 and FGF20. The red line shows the different 
reflective index (dRI). The blue line indicates the molecular mass of FGFs. 
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The FGF2 mutants where basic amino acids of heparin binding sites were mutated to 
alanine were measured and analysed by SEC-MALLS. The results show there was 
little difference in the molecular mass between the FGF2 mutants and the natural 
FGF2: FGF2 HBS2 (18.7 kDa) and FGF2 HBS3 (21 kDa), though there was a 
degree of peak broadening for FGF2 HBS3 (Figs 3.7A and 3.7B). This indicates that 
the mutation of the basic residues did not alter the oligomeric state of the FGF2. The 
FGF4 (13.7 kDa), FGF10 (kDa), Halotag-FGF6 (56.4 kDa) and FGF17 (23.2 kDa) 
were also analysed and the results show that these are all present as monomers (Fig. 
3.7). 
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Figure 3.7 The average molecular mass per volume unit and the differential 
refractive index of FGFs (FGF2 mutants, FGF4, FGF10, Halotag-FGF6 and 
FGF17). The red line shows the different reflective index (dRI). The blue line 
indicates the molecular mass of FGFs. 
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Chapter 4 Heparin binding preference and 
structures in the fibroblast growth factor family 
parallel their evolutionary diversification 
In Chapter 4, FGF-3, FGF-4, FGF-6, FGF-10, FGF-17, FGF-20, have been used as a 
defined system subjected to natural selection, to determine the specificities of their 
interactions with HS. This was measured from two perspectives. First, the heparin 
structures required for binding by these FGFs was measured by differential scanning 
fluorimetry, using a library of modified heparins and model glycosaminoglycans. 
Second, the extent of the primary canonical heparin binding site and the types of 
secondary heparin binding sites on these FGFs were determined by a lysine-targeted 
protect and label approach. By extending the analyses to these 6 paracrine FGFs, it 
will then be possible to combine the data with previous ones 
[34]
 and so provide a 
reasonable coverage of the FGF family: at least two FGFs from each subfamily. In 
this way it should be possible to determine the extent to which there is specificity 
and selectivity in the interactions of FGFs with HS and whether these correlate with 
the FGFR isoform binding properties of the FGFs and their phylogeny based on 
amino acid sequence, which is a major aim of this thesis (Section 1.9). This work 
will also provide insight into the broader question of specificity of the interactions of 
proteins with heparin and HS and provides the first set of data that will enable a later 
(Chapter 7) critical evaluation of what sulfated sequences of saccharides in HS 
actually mean from the perspective of protein binding. 
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4.1 Paper: Heparin binding preference and structures in 
the fibroblast growth factor family parallel their 
evolutionary diversification 
 
Y. Li, C. Sun, E. A. Yates, M. C. Wilkinson, and D. G. Fernig, 'Heparin binding 
preference and structures in the fibroblast growth factor family parallel their 
evolutionary diversification, Open Biol, Submited (2015). 
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Abstract 
Heparan sulfate (HS) is key to the regulation of the functions of a large number (883) of 
extracellular regulatory proteins. However, the level of specificity of the protein-
polysaccharide interactions and whether such specificity is of functional significance is still 
debated. As a family, the fibroblast growth factors (FGF) bind HS and they have a clear 
phylogenetic relationship at the level of amino acid sequence, which is mirrored in their 
functions. We have used members of the FGF family (FGF-3, FGF-4, FGF-6, FGF-10, FGF-
17, FGF-20), as a defined system subjected to natural selection, to determine the specificities 
of their interactions with HS. Using a library of modified heparins and other 
glycosaminglycans, differential scanning fluorimetry and a protect and label strategy, it is 
clear that the FGFs from the same subfamily selectively bind oligosaccharide structures of 
similar sulfation pattern and length, whereas FGFs from different subfamilies have more 
divergent selectivity. Moreover, analysis of polysaccharide binding sites on the FGFs 
demonstrates that the presence and type of secondary binding sites is similar in FGFs from 
the same subfamily, but differs between subfamilies. The results demonstrate that specificity 
and selectivity underlies the interactions between FGFs and HS. Moreover, the data show 
that the molecular basis of the binding of FGFs to HS is likely to have been subjected to the 
same selection pressures that drove the expansion and divergence of the FGF family and 
their selectivity for particular isoforms of their receptor tyrosine kinase during the evolution 
of complex animals. 
 
Keywords: Heparan sulfate (HS), fibroblast growth factor (FGF), specificity, heparin 
binding site; 
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Introduction 
The glycosaminoglycan heparan sulfate (HS) regulates many aspects of cell communication 
by means of binding to over 883 extracellular proteins and thereby controlling their activities 
[113, 114, 156, 172, 173]. Two classic examples are the activation of antithrombin III by the 
polysaccharide, which contributes to the regulation of coagulation [174] and the control of 
the transport and effector functions of the paracrine fibroblast growth factors (FGFs) by their 
binding HS [119, 120]. A major challenge is to understand the structural basis of the 
interactions of proteins with HS and to what extent any molecular specificity and selectivity 
of these interactions is of functional significance. 
HS consists of repeating disaccharide units joined by 1-4 linkages. The HS chains are always 
synthesized attached to a core protein to form heparan sulfate proteoglycans (HSPGs). It is 
the core protein that directs the HS chains to their functional location, which can be the cell 
surface or the extracellular matrix. Heparin, often used as an experimental proxy for HS on 
account of its underlying structural similarity, nevertheless is a more sulfated structure. The 
repeating units of HS consist of a glucuronic acid (GlcA) or its C5-epimer IdoA, and D-
glucosamine (GlcN). The glucosamine may be N-acetylated (GlcNAc), N-sulfated (GlcNS), 
or unsubstituted (GlcN). The sugar chain is modified by the N-deacetylase / N-
sulfotransferases (NDSTs) to replace the N-acetyl group of glucosamine with a sulfate group 
[115, 175, 176] and may be followed by C5 epimerization with C5 epimerase [107] and O-
sulfation with  2-O, 3-O and the 6-O sulfotransferases [108, 109]. Since all the other 
modifications depend on the presence of N-sulfated glucosamine, the result is that HS chains 
have a domain structure: NA domains of no sulfation structure, NS domains of highly 
sulfated structures, and NA/NS domains comprising mixed disaccharides of GlcNAc and 
GlcNS [175, 177]. The sulfated structures are of functional significance, forming the protein 
binding domains [113]. 
The FGF family of 22 proteins has been divided into 7 subfamilies by phylogenetic analysis 
[29, 31]. Based on their action mechanism, FGFs can be classified into three types: 
intracrine, paracrine and endocrine. Only the paracrine FGFs bind to HS. Evidence for 
control by HS of FGF transport comes from a variety of experimental system. For example, 
mutations in gene encoding sugarless (sgl) and sulfateless (sfl), which are indispensable in 
the process of heparan sulfate chain biosynthesis, were identified as producing similar 
phenotypes to Wingless (Wg) or Hedgehog (Hh) signalling mutants [115]. Interactions with 
HS, which are occurred in the extracellular matrix, regulate the diffusion of FGFs [171, 178] 
and so can determine the shape of FGF concentration gradients in development [179, 180], 
as well as the storage and release of FGFs in tissue homeostasis [181, 182], The growth 
factor/morphogen type signals generated by FGFs require the assembly of the ternary 
complex of FGF ligand, FGF receptor (FGFR) and HS, which engages both the ligand and 
receptor [118, 125, 164, 165]. Thus, in this respect, HS acts as a co-receptor. 
In terms of the specificity of interactions of proteins with HS there are different paradigms 
and views. One paradigm is the activation of antithrombin III by its binding to a specific 
pentasaccharide sequence [163], which has been successfully transformed into a synthetic 
anticoagulant, Arixtra [183, 184]. It was the higher affinity saccharide unit salt-eluted from 
an antithrombin III affinity column that was originally identified, but it was not the only 
sequence that bound antithrombin III and able to activate it. More recent findings are that 
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activity relates to thermal stabilisation of antithrombin III [185] and many oligosaccharide 
structures have now been shown to possess both a high affinity for antithrombin III and to 
exert strong anticoagulant activity [186, 187]. With other proteins there is even less 
consensus. Thus, with FGFs highly specific binding structures in heparin and in HS have 
been sought [188]. In other experiments, however, the conclusion was that the charge 
density of the polysaccharide was the major determinant of binding selectivity [162].  
In a recent attempt to understand the extent, if any, of selectivity of FGFs for binding to HS, 
the molecular basis of the interactions between six FGFs from five subfamilies and HS was 
characterized in depth. This work suggested that there is a degree of selectivity in FGF-
heparin interactions and this reflects the evolution of the FGF family members [34], which 
parallels the specificity of FGF ligands for FGFRs [169].  
However, this work is limited in its coverage: two FGFs from one subfamily and one from 
each of four other subfamilies. Therefore, alternative explanations are quite possible. 
Consequently, here we characterize the interactions with HS of a further six FGFs from two 
perspectives. The preference of FGFs for particular sugar structure has been determined 
using differential scanning fluorimetry (DSF) and a library of chemically modified heparins, 
heparin derived oligosaccharides and model glycosaminoglycans. A protect and label 
approach is then used to identify lysine side chains involved in heparin binding and so map 
the primary and secondary HS binding sites in the FGFs. Pooling the present data with those 
acquired previously [34] demonstrates that the FGFs show clear selectivity for binding 
structures and that this, along with the pattern of secondary binding sites on the surface of 
the FGFs follows the phylogeny established by amino acid sequence alignment. Thus, the 
molecular basis of the interactions of FGFs with HS, with their preference for particular 
isoforms of the FGFR has followed the expansion and specialization of the FGF family that 
occurred during the course of the evolution of the more complex body plans of animals. 
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Experimental procedures: 
Materials Heparin (17 kDa average molecular mass, Celsus Lab, Cincinnati, OH) was used 
in all assays and as the starting material for the production of modified derivatives and 
oligosaccharides. Different chemically modified heparin derivatives D1-9 (Table 1; [189]) 
and cationic forms were produced, as described (Rudd, T.R., 2007) while oligosaccharides 
with degrees of polymerization (dp) dp 2 to dp 12 were obtained from Iduron (Manchester 
UK). Porcine mucosal heparan sulfate (HS) and hyaluronic acid (HA) were from Sigma (St. 
Louis USA); chondroitin sulfate (CS) and dermatan sulfate (DS) were from Iduron. 
Recombinant human FGFs  
cDNA encoding Histag-FGF-4 (UniProt accession number P08620; residues 31-206) was 
transformed into C41 (DE3) cells and expressed by inducing with 1 mM isopropyl 1-thio-
beta-D-galactopyranoside at 37°C for 3 h. After cell lysis by sonication and clarification by 
centrifugation, the supernatant was loaded onto an affinity chromatography HiTrap heparin 
HP column (GE Healthcare, Amersham, Bucks, UK). FGF4 required further purification 
with a cation-exchange HiTrap 1 ml SP HP column to remove the contaminants, as describe 
previously (Uniewicz paper). HaloTag (HT)-FGF17 and HaloTag (HT)-FGF6 were 
expressed and purified as described [171], the HT-FGF17 protein was digested overnight by 
mixing with TEV protease at ratio 40:1. The sample was then loaded on a HiTrap Q column. 
FGF17 eluted in the flow through fraction since it did not bind to this anion-exchange matrix, 
whereas the HaloTag protein bound to the column. The FGF-17 was then further purified by 
affinity chromatography a Hitrap Heparin column. Histag-FGF-3, HaloTag (HT)-FGF6, 
Histag-FGF-10, and Histag-FGF-20 were expressed and purified, as described [171]. 
Size exclusion chromatography-multi-angle laser light scattering (SEC-MALLS) 
Analysis of the solution molecular mass were performed by separation of proteins on 
Superose 200 HR10/300 columns (GE Healthcare) connected in series with a Wyatt 
Dawn8+ and Wyatt Optilab T-rEX (Wyatt Technology) at 22°C. Samples (100 µL) were 
filtered and then applied to the column, which was developed in 150 mM NaCl buffer with 
either 50 mM HEPES or 50 mM Tris-Cl, both pH 7.4 at a flow rate of 0.75 mL/min. 
Differential Scanning Fluorimetry (DSF) 
DSF was performed with a 7500 Fast Real-Time PCR (RT-PCR) instruction (software 
version 1.4.0 Applied Biosystems), as described [34, 190]. The different sugars (100 µM, 
3.5 µL in HPLC grade water) and FGFs (50 µM, 3.5 µL) as ten-fold concentrated stock 
solutions, phosphate-buffered saline (PBS, NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM, 
KH2PO4 1.8 mM; 24.5 µL), and freshly prepared 100-fold stock solution Sypro Orange dye 
(3.5 µL) (Life Technologies Ltd) were added to a Fast Optical 96 Well Reaction plate (Life 
Technologies Ltd) kept on ice. After sealing with Optical Adhesive Film (Life Technologies 
Ltd), the plate was directly analysed in the RT-PCR instrument with a heating cycle 
covering a gradient between 32 and 81°C in 99 steps of 20 s. First derivatives of the melting 
curves were calculated with Origin 7 (OriginLab Corp., Northampton, UK). For each sugar, 
at least two experiments each in triplicate was performed and analysed. The mean melting 
temperature Tm and the standard error (S.E.) were calculated based on the six repeats. Data 
were normalized as: [Tm x-Tm PBS] /[Tm hep- Tm PBS], where Tm x is the Tm of protein 
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in the presence of the heparin derivative; Tm PBS is the Tm of the protein in PBS, and Tm 
hep is the Tm of the protein in the presence of heparin. The relative stability of protein in 
PBS buffer was set to 0, while the relative stability of the protein in the presence of heparin 
was set to 1. 
Protect and label identification of lysines involved in heparin binding 
Lysine protection: The identification of lysines in heparin binding sites (HBS) was according 
to Ori et al.
[170]
 with minor modifications. A heparin minicolumn was made by placing a 
plastic air filter at the end of a small pipette tip into which 30 µL of AF-heparin beads 
(Tosoh Biosciences GmbH, Stuttgart, Germany; binding capacity 4 mg antithrombinIII/mL 
resin) was packed. A 5 mL syringe was used to pack the minicolumn and dispense buffer. 
The heparin column was equilibrated 4 times with 50 µL of PB 150 buffer (17.9 mM 
Na2HPO4, 2.1 mM NaH2PO4, 150 mM NaCl, pH 7.8). A minimum of 40 µg FGF protein 
was loaded onto the heparin column and the loading was repeated 3 times with the same 
sample. After binding, the column was washed with PB 150 buffer 4 times. To acetylate 
exposed lysines, the minicolumn was then quickly rinsed with 20 µL of PB 150 containing 
50 mM sulfo-NHS-acetate (Life Technologies, Paisely UK) and then incubated for 5 min 
with 20 µL of fresh PB 150 containing 50 mM sulfo-NHS-acetate at room temperature. 
After acetylation, the minicolumn was washed with 50 µL of PB 150 buffer and acetylated 
protein was eluted from heparin with 2 x 20 µL elution buffer (45 mM Na2HPO4, 5 mM 
NaH2PO4, 2 M NaCl, pH 7.8). 
HBS Lysine Biotinylation: Acetylated protein was diluted with 200 µL of PB buffer and 
concentrated with a 5 kDa MWCO centrifugal filter (Sartourius Ltd., Epsom, UK) by 
centrifugation for 15 min at 11200 x g. The volume was adjusted to 37.2 µL with PB buffer 
and any remaining amino groups were biotinylated by the addition of 2.8 µL 145 mM NHS-
biotin (Life Technologies, Paisely UK) in dimethylsulfoxide and 30 min incubation at room 
temperature. The biotinylation reaction was quenched with 4 µL of 1 M Tris, pH 7.5. Then, 
the sample was transferred to a desalting centrifugal column (7 kDa MWCO, Thermo 
Scientific, Rockford, UK), covered with 70 µL HPLC grade water and centrifuged for 2 min. 
Samples were frozen at -80°C for 10 min and dried by centrifugal evaporation. 
Protein Digestion: Dried sample was dissolved with 25 µL 8 M urea, 400 mM NH4HCO3, 
pH 7.8 and 2.5 µL 45 mM DTT and incubated for 15 min at 56°C. Then, the samples were 
carbamidomethylated with 2.5 µL of freshly made 0.1 M iodoacetamide for 15 min at room 
temperature in the dark. Proteins were diluted with 70 µL of HPLC grade water and digested 
overnight with 1 µg of MS-grade protease (trypsin, chymotrypsin, thermolysin or Glu-C, 
Promega UK). 
Identification of Labelled Peptides: Biotinylated/acetylated peptides were made up to 0.5 % 
(w/v) trifluoroacetic acid (TFA) and desalted using C18 Zip Tips (Millipore). The latter 
were pre-wetted with 100 % (v/v) acetonitrile (ACN) and then pre-equilibrated with 0.1 % 
(w/v) TFA in water. The peptides were loaded on the Zip Tip and then washed with 10 µL 
0.1 % (w/v) TFA. Finally, these peptides were eluted with 2 aliquots of 4-6 µL 50 % (v/v) 
ACN. The samples were concentrated by rotary evaporation. Analyses were performed on a 
MALDI-TOF mass spectrometer (Waters, Corp., Manchester, UK). The MS spectra were 
produced by MassLynx v4.0 and then analysed with the MS-digest tool of the Protein 
  
 
94 
Prospector package v 5.12.4 with the following parameters: considered modification, acetyl 
(K), biotin (K), carbamidomethyl (C), carboxymethyl (C); protease used, 
trypsin/chymotrypsin, thermolysin or Glu-C; missed cleavages, 5; minimum-maximun mass: 
800-4000. 
 
Results: 
We have used two approaches and multiple representatives of the different human heparin-
binding FGF subfamilies, FGF-3 and -10 (FGF-7 subfamily), FGF-16 and -20 (FGF-9 
subfamily), FGF-4 and -6 (FGF-4 subfamily), and FGF-8 and -17 (FGF-8 subfamily) to gain 
an insight into the selectivity and structural basis of the interaction of FGFs with 
glycosaminoglycans. DSF makes use of a sensitive dye (Sypro Orange), which when bound 
to aromatic residues produces a high fluorescence; these residues are exposed when proteins 
are thermally denatured [190]. This allows measurement of the extent of stabilization of the 
structure of FGFs that occurs upon binding different glycosaminoglycan structures. The 
protect and label approach identifies lysine residues that are engaged in direct interactions 
with heparin and so determines the likely binding sites of the polysaccharide in the FGFs. It 
is capable of identifying lysine residues in both the primary, higher affinity canonical 
binding site and the much lower affinity secondary binding sites [34, 170]. 
 
Thermal stabilization of FGFs by interaction with heparin 
The change in fluorescence was measured as temperature was increased with 5 µM of each 
FGF, and then the first derivative was calculated to determine the melting temperature. Only 
one melting curve and corresponding derivative per sample is shown in the figures for 
clarity. Complete data sets are shown in supplementary data. These experiments show that 
heparin has a concentration-dependent effect on the thermal stability of all the FGFs tested, 
since their melting temperature progressively increased as the concentration of heparin 
increased. The melting temperature (Tm) of FGF3 and FGF17 is 36°C and 37.5°C, 
respectively, while the Tm of FGF4 (49.5°C), FGF10 (41.6°C) and FGF20 (52.2°C) [191, 
192] is considerably higher (Figs 1D). In the case of FGF6, the protein aggregates when the 
N-terminal HaloTag fusion protein is removed [171], so the DSF assay was performed on 
the fusion protein. Two distinct peaks are observed, one at 46.5°C and the other at 58.5°C 
(Fig. 5B). The lower melting temperature (46.5°C) is assigned to FGF6 for two reasons. 
First, the Tm of purified HaloTag corresponds to the second peak (Fig. S3B), whereas the 
peak at 46.5°C is shifted to higher temperature when the protein is incubated with heparin 
(Fig. 5A) and only the FGF6 moiety binds the polysaccharide [171]. Thus, not only are 
FGF4, FGF6, FGF10 and FGF20 more stable than FGF3 and FGF17 in the absence of 
heparin, but interestingly, human FGF3 and FGF17 would be under these conditions 
unstable at normal body temperature (Fig. 1D).  
To determine the effects of binding heparin, a range of heparin concentrations (0-100 µM) 
was tested against a fixed concentration (5 µM) of FGFs and the melting temperature was 
calculated at each concentration of polysaccharide. The melting curves show that a 
stabilizing effect of heparin on FGF3 and FGF10 is apparent from 0.5 µM heparin (heparin-
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FGF molar ratio: 1:10) to 2.5 µM heparin (heparin-FGF molar ratio: 1:2) and is then 
unchanged at higher concentrations of heparin (Fig. 1C and supplemental Fig. S1C). The 
melting temperature of FGF6 was increased by heparin though the signal from the more 
stable HaloTag confounded that from FGF6 when the latter was fully stabilised by heparin. 
Therefore, this approach could be used to measure the relative stabilizing effect interaction 
of FGF6 with glycosaminoglycans. The effect of heparin on the melting temperature of 
FGF4, FGF6 and of FGF17 is similar, with stabilization becoming apparent at 0.5 µM 
heparin and reaching a maximum around 2.5 µM heparin. However, the stabilizing effect of 
heparin on FGF20, which is apparent at 0.5 µM heparin does not reach a maximum even 
with 100 µM heparin, and so is distinct from the other four FGFs. The thermal stabilization 
of FGF-20 by heparin was the lowest at 10°C, whereas for FGF4, FGF6, FGF10 and FGF17 
it ranged from 11°C-15°C and was 17°C for FGF3. Thus, in the case of FGF3 and FGF17, 
binding to heparin raises their melting temperature well above body temperature.     
       
Analysis of sugar binding selectivity by DSF 
The structures in the polysaccharide required for binding these FGFs were then determined 
by measuring the stabilization effect of a library of model glycosaminoglycan and their 
derivatives. The molar ratio of FGF: polysaccharide used in this experiment was 
approximately 1:2 (FGF, 5 µM; polysaccharide, 10 µM).  
FGF-3, a member of the FGF7 subfamily according to amino acid sequence alignment was 
similarly stabilized by unmodified heparin and any of the singly desulfated heparins (D2, D3 
and D4) (Fig. 2a). However, the doubly desulfated heparins with just a 6-O-sulfate or N-
sulfate (D5 and D7) stabilized FGF-3 to 40 % and 25 % of the level observed with heparin 
respectively, whereas heparin with just 2-O-sulfate was without a detectable effect. Totally 
desulfated heparin was also without effect. FGF3 was most stabilized by persulfated heparin, 
whereas HS was as effective as the doubly desulfated N-sulfated or 6-O sulfated heparins, 
D5 and D6. FGF-3 did not have a detectable interaction with HA or CS, but DS clearly does 
bind, albeit not as well as HS. A dp 4 was the shortest oligosaccharide able to stabilize FGF-
3 with a maximum effect at dp 10, which stabilized FGF-3 to an extent similar to full-length 
heparin. FGF3 did not discriminate between the different cationic forms of heparin, since 
these all had the same stabilizing effect (Fig. 2C). Thus, FGF3 has a clear preference for a 
saccharide structure with any two of N-, 2-O and 6-O sulfate and is able to bind structures 
with doubly desulfated heparin containing just a 6-O-sulfate or an N-sulfate, while a dp 10 is 
likely to represent the full-length binding structure in the polysaccharide.  
In the case of FGF10, another member of the FGF7 subfamily, there was no discernible 
difference in the stabilizing effect of heparin and the singly desulfated heparins (D2, D3 and 
D4) (Fig. 3a). However, all three doubly desulfated heparins (D5, D6 and D7) had a similar 
stabilizing effect, which was ~50 % to 70 % of that seen with heparin. Totally desulfated 
heparin and HA failed to bind FGF10, whereas FGF10 bound persulfated heparin more 
effectively than heparin and HS only slightly more weakly. FGF10 also bound both CS and 
DS, though the former more weakly. A heparin derived dp 4 oligosaccharide provided 
substantial binding and maximum binding was seen with a dp 8, indicating that this is the 
likely minimum sized fragment of the polysaccharide required for interaction. FGF10 may 
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also have a slight preference for the Ca
2+
, Zn
2+
 and Cu
2+
 cation forms of heparin. Thus, the 
binding preferences of FGF10 are similar, but not identical to those of FGF3. Compared to 
FGF3, FGF10 has a less marked preference for singly over doubly desulfated heparins, it 
does not appreciably prefer any of the three doubly desulfated heparins and has a wider 
range of GAG species (CS as well as DS) with which it can interact (Figs 1B, 1C, 2B, 2C). 
For FGF4, there was a greater thermal stabilization by heparin than by any of the singly 
desulfated heparins (Fig. 4A). Moreover, amongst the singly desulfated heparins, FGF4 had 
a preference for polysaccharides with both 2-O and N- sulfate (D4) over polysaccharides 
with N-sulfate and 6-O sulfate (D3), or 2-O and 6-O sulfate (D2). There was no appreciable 
effect of the doubly desulfated heparins on the thermal stability of FGF-4. These data 
suggest that the core recognition structure of FGF4 in the polysaccharide involves a 2-O and 
N-S sulfated structure. The lower stabilization observed with HS may reflect that sequences 
of the appropriate length containing this motif are relatively rare in this material. FGF4 also 
bound DS, though weakly, and did not bind to HA or CS (Fig. 4A). FGF4 did not interact 
detectably with a dp 4 and a dp 6 was the minimal fragment required for binding. Maximal 
binding, equivalent to that observed with heparin was achieved with a dp 12 (Fig. 4B). Little 
effect was observed for the different cation coordinated forms of heparin, indicating that this 
parameter, which changes the conformation of the polysaccharide chain [193], does not, at 
least in the case of the heparin polysaccharide, influence the binding of FGF4 (Fig. 4C). 
FGF6 is another member of the FGF4 subfamily, the singly desulfated heparins stabilized 
FGF6 more than doubly desulfated heparin. FGF6 showed a strong preference for the 
combination of 2-O and 6-O sulfated and 2-O and N-sulfated heparin. With the exception of 
2-O-sulfated heparin, the doubly desulfated heparins barely stabilized FGF6, which 
highlights the preference of FGF6 for a structure containing 2-O-sulfate. FGF6 was also 
stabilized by HS in a similar manner to heparin, whereas HA, CS and DS did not produce 
any detectable stabilization of FGF6 (Fig. 5C). The minimum size and maximum size of 
oligosaccharide required for binding to FGF6 was dp 6 and dp 12, respectively (Fig. 5D). 
FGF17 bound the three singly desulfated heparins similarly to heparin and the doubly 
desulfated heparins more weakly (Fig. 6A).  Moreover, FGF17 has a mild preference for 
heparin with either a 2-O or a 6-O sulfate, compared to heparin with just an N-sulfate (Fig. 
5A). FGF17 did not bind desulfated heparin or HA, but bound persulfated heparin and HS 
similarly to heparin. It also interacted with DS to a similar extent as the singly desulfated 
heparins and more weakly with CS. FGF17 required at least a dp 4 oligosaccharide for 
binding and maximal binding was observed with a dp 8. It may have a slight preference for 
Zn
2+
 coordinated heparin over other cationic forms of the polysaccharides (Figs 6B & 6C). 
Heparin was more effective at stabilizing FGF20 than any of the singly desulfated heparins 
(Fig. 7A). FGF20 had a weak interaction with the doubly desulfated heparin possessing just 
6-O-sulfate or 2-O-sulfate, whereas there was no detectable interaction with just a N-sulfate, 
which suggests a preference for the former two sulfation positions. The stabilizing effects of 
CS and DS on FGF20 were similar to that seen with HS. The minimum size of 
oligosaccharide required for binding to FGF20 was dp 10 whilst the maximum size of 
oligosaccharide used in this assay, dp 12, only stabilized the protein to around 40 % of the 
extent observed with heparin (Fig. 7B). The binding of FGF20 to the polysaccharide was 
markedly affected by the coordinating cations: the divalent cation (Ca
2+
, Zn
2+
 or Cu
2+
) 
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coordinated heparins were twice as effective in stabilizing FGF20 as heparins coordinated to 
a monovalent cation (Na
1+
 and K
1+
) (Fig. 7C). 
 
Identification of lysines involved in heparin binding by protect and label 
The lysine residues involved in binding heparin in the FGFs were determined by the “protect 
and label” approach, where lysines in binding sites are protected with acetyl groups whilst 
the FGFs are bound to heparin [170]. Following release of the FGF from heparin, the newly 
exposed lysines that had been involved in binding are labelled with biotin and identified by 
mass spectrometry. 
FGF7 Subfamily (FGF3/FGF10) 
Initial experiments with FGF3 and FGF10 identified just one peptide with biotinylated 
lysines, Lys-47 in FGF3 and Lys-81 in FGF10 both in strand β1 (Table 2). This was 
considered to be due the use of chymotrypsin to cleave the protein, which may produce 
peptides from these FGFs that are either too long or too short for detection with MALDI-MS. 
To identify further peptides, FGF3 and FGF10 were digested with trypsin (cleaves at Arg 
residues only, due to the protect and label procedure) and thermolysin (cleaves at Pro, His, 
Asp, Glu residues), as modifications of the published method [170]. By changing the 
protease used to cleave the lysine modified protein, a substantial number of biotinylated 
lysine residues were identified in FGF3. Lys-160, Lys-168, Lys-174, Lys-204, and Lys-214 
were found to be biotinylated. These residues are located the loops between strands β10 and 
β11 and between strands β11 and β12 and C-terminal to strand β12. They correspond to the 
HBS1 of FGF-3, predicted by sequence alignment (Fig. 12) [34].  In addition, two other 
lysine residues, which are close to the above residues of the canonical HBS1 were biotin 
labelled: Lys-53, which lies between strands β1 and β2, and Lys-101, which is between 
strands β6 and β7. Thus, these two residues are likely to be part of the canonical binding site, 
which has contributions from residues that are distant in the primary sequence, but 
neighbouring in the folded protein. However, biotinylated Lys-47 on strands β1 is distant 
from the canonical binding site. Along with the neighbouring arginine (Arg-44-46), this 
would be part of the secondary binding site termed HBS3. The amino acids in FGF3 
corresponding to HBS4 identified in FGF7 are arginine and asparagine (Fig. 12, [34]), which 
would not be detected by the lysine targeted protect and label used here. Thus FGF3 may 
also possess and HBS4, but this remains to be established. 
Lys-87, Lys-184, Lys-191, and Lys-195 were all labelled in FGF10 (Table 2). These lysine 
residues are in the canonical HBS1 of FGF-10, as predicted by sequence alignment (Fig. 8). 
Three lysines of the peptide “131YLAMNKKGKLY141” (Lys-125, Lys-126 and Lys-128) of 
FGF10 were found to be both acetylated and biotinylated (Fig. 8). This has been observed 
previously [170, 194] and is considered to be due to the local dissociation of a lysine side 
chain from its interaction with the polysaccharide. In the presence of the NHS-acetate used 
in the protection step, it becomes acetylated this would likely preclude its re-binding to the 
polysaccharide. Since the protein remains bound, these lysines must form part of the binding 
site that is relatively dynamic over the time-scale of the protection step, whereas the 
remainder of the binding site is not. Two biotinylated lysines were also identified in peptide 
“IEKNGKVSGTK” (residues, 92-102). Owing to the position of these residues on the 
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surface of FGF10, they are most likely to form part of HBS4, as identified in FGF7 
previously [34] and in FGF3 in the present work (Fig. 8). HBS4 lies orthogonal to HBS1 in 
all three proteins, thus the binding of the polysacchasride to these sites is mutually exclusive. 
Similar to FGF3, the biotinylated Lys-81 located in strand β1 has also been identified to be 
part of HBS3. Since the aligned HBS3 on FGF7 has arginine residues rather than lysines, it 
was not detected. The identification of HBS3 in FGF3 and FGF10 strongly suggests that the 
corresponding sequence in FGF7 has the same function. 
FGF4 subfamily (FGF4/FGF6) 
For FGF4, Lys-183, Lys-186, Lys-188 and Lys-189 in the area between β10 strand and β12 
strand were found to be biotinylated (Table 3). These lysine residues correspond to the HBS-
1 of FGF4 predicted by sequence alignment (Fig. 9). The mutation to alanine of Lys-183 and 
Lys-188 in FGF4 had previously identified these residues as being part of the canonical 
HBS-1 [195]. Moreover, another three labelled lysine residues are physically adjacent: Lys-
142 is in the loop between β6 strand and β7 strand; Lys-144 is on the β7 strand; Lys-147 is 
in the loop between β9 strand and β10 strand. These six residues can be considered to 
delineate the canonical HBS-1 of FGF4 (Fig. 9). Further biotinylated lysines (Lys-65, Lys-
81 and Lys-158) were identified. These three lysines are physically adjacent, but distant 
from the residues in HBS1. They are aligned with a secondary HBS, HBS3, in other FGFs 
(Fig. 12) [34, 170]. Similar to FGF4, FGF6 has two heparin binding sites: HBS1, which is 
identified by biotinylated Lys-144, Lys-185 and Lys-194 (separately, loop between β6 strand 
and β7 strand, area between β10 strand and β12 strand); HBS3, which includes Lys-83 
towards the N-terminal of strand β1 and Lys-158 on the β8 strand (Fig. 9). 
FGF8 subfamily (FGF17) 
In the case of FGF17, the predicted canonical HBS1 contains arginine, but no lysine residues 
and, therefore, no peptides were identified between strands β10 and β12. However, Lys-82 
and Lys-85, located in the loop between strands β3 and β4, Lys-100 on strand β5, Lys-106 
on strand β6 and Lys-119, Lys-123 and Lys-125 on strand β7 and the loop between strands 
β7 and β8 were all found to be biotinylated. These residues are physically adjacent to the 
region between strand β10 and β12, where the core of the HBS1 of FGFs is predicted to be 
located. In addition, FGF17 has an HBS2, which includes Lys-176, Lys-191 and Lys-193 at 
the C-terminus. The aspartic acid (Asp-121) of FGF18 enlarges the negative border formed 
by two glutamic acid (Glu-103 and Glu-105), the result of which is that Lys-82 and Lys-100 
are part of FGF18’s extended HBS2. In contrast, Asp-121 of FGF18 is Ser-121 in FGF17, 
which consequently has a smaller negatively charged border along its HBS1 and Lys-82 and 
Lys-100 are now part of an extended HBS1. These data demonstrate how changes in the 
residues surrounding HBS1 (in this instance Asp to Ser) can alter the structure of an HBS 
and provide subtle difference between members of the same subfamily (Fig. 10). 
FGF9 subfamily (FGF20) 
For FGF20, Lys-183, Lys-197, Lys-208 and Lys-212 located in strand β9, the loop between 
strand β10 and strand β11, and the loop between strand β11 and strand β12 were biotinylated 
and these correspond to the predicted HBS1 by sequence alignment [34]. Two further lysine 
residues (Lys-148 and Lys-183) that are located in the area between strand β6 and strand β7 
were also identified to be biotinylated. Since these two lysines are physically adjacent to the 
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canonical binding site, they were considered to be an extension of the HBS1. The 
biotinylated Lys-231 located in the C-terminus are quite close to Arg-90, Arg-91 and Arg-92, 
which may form the HBS3 (Fig. 11). However, arginine residues cannot be identified by the 
NHS chemistry used here. In any event, FGF20 possesses a single, enlarged HBS-1, similar 
to FGF9 [34], and may also possess an HBS3. The equivalent residue in FGF9, Lys- was not 
found to be labelled in previous work [34], which may be either due to only one protease 
being used in this work or to the existence of a very well defined negatively charged border 
around this residue in FGF20. FGF20 has been found to exist as a non-covalent dimer in 
solution [192], which is also true for the protein we have produced (Fig. S6). When the 
enlarged HBS1 is mapped onto the dimer structure, the HBS1 from both FGF20 monomers 
are joined to form a single large heparin binding surface. 
 
Discussion 
To resolve the extent to which molecular specificity underpins the interactions of proteins 
with HS we have used the phylogenetic relationship of the FGF family, established from 
amino acid sequence as a test bed. The interactions of FGFs and heparin/HS have been 
measured from two perspectives: the structures in the polysaccharide required for binding 
and that lysines in heparin binding sites on the FGFs. 
Taking the present results with previous ones [34] provides a comprehensive coverage of the 
paracrine FGFs, all of which bind HS, with at least two FGFs from each of the subfamilies 
analysed. Collectively these data follow a clear pattern. FGF members from the same 
subfamily have a preference for binding similar patterns of sulfation and length of 
oligosaccharide whereas FGFs from different subfamilies have much more pronounced 
differences in these preferences (Fig. 13). Moreover, FGFs from the same subfamily possess 
similar secondary HS binding sites and their primary HBS1 have similar architectures. 
Again, FGFs from different subfamilies have different combinations of secondary HBSs and 
their HBS1 differs, particularly with respect to the extent to which amino acids that are 
distant in sequence, but physically close contribute to the HBS1 (Fig. 13). Thus, in the FGF1 
subfamily, both FGF1 and FGF2 have similar preference for N-sulfate and 2-O-sulfate, but 
FGF1 differs in that is also binds saccharide structures with 6-O-sulfated heparin [190]. This 
subfamily possesses three heparin binding sites, the primary HBS1 and the secondary 
binding site HBS2 and 3 [34, 42, 170]. In the FGF4 subfamily, FGF4 prefers structures 
containing 2-O and N-sulfate, whereas FGF6 binds strongly to 2-O and 6-O-sulfated heparin. 
Compared to FGF4, FGF6 needs a slightly large structure for minimum binding (dp 6). Both 
FGF4 and FGF6 have a single secondary binding site, which would correspond to HBS3 in 
the FGF1 subfamily. In the case of the FGF7 subfamily, FGF7 and FGF10 have preference 
for a similar sulfate pattern and length of oligosaccharide. However, FGF3 barely binds to 
doubly desulfated heparin containing only 2-O-sulfate and it required larger structure for full 
binding. The putative HBS3 of FGF7 and HBS4 of FGF3 contain arginine, but not lysine [34] 
(Fig. 12), which cannot be identified by our lysine targeted method. The protect and label 
data, when combined to sequence alignment (Fig. 12) indicate that the FGF7 family 
possesses two secondary heparin binding sites, HBS3 and HBS4, the latter being physically 
orthogonal to the canonical HBS1. FGF17 and FGF18, which are in the FGF8 subfamily 
bind to similar structures containing 6-O-sulfate and N-sulfate and they contain a single 
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secondary binding site, HBS2. In the FGF9 subfamily, FGF9 and FGF20 show similar 
preference to 6-O-sulfate heparin. FGF9 prefers to bind with N-sulfate rather than 2-O-
sulfated heparin, in contrast, FGF20 binds strongly to 2-O-sulfated heparin. Although 
FGF20 required larger structures for binding than FGF9, this could be caused by its dimer 
structure. Both FGF9 and FGF20 possess a single, enlarged HBS1. A secondary HBS3 was 
also been found in FGF20; whereas corresponding basic residues are present in FGF9, in the 
latter there is no negatively charged border and so they are more likely to be part of an 
extended HBS1. In contrast in FGF20, these residues are surrounded by a negative border, 
which would isolate them. Consequently, FGF20 seems likely to have a distinct HBS3. 
The expansion of the FGF family and its divergence into subfamilies occurred through 
genome duplication events that led to even more complex animal body plans [33]. It is clear 
that the molecular specificity of the FGFs for particular structures in HS and the pattern of 
secondary binding sites on the FGFs also underwent the similar diversification. This implies 
that the differences we observe (Fig. 13) are linked to the functional differences that exist 
between FGF subfamilies. It is important to note that the molecular specificity is far from 
absolute. That is, there is a consensus ranking of sulfations, oligosaccharide length and GAG 
preference for FGFs in the same subfamily. This is similar to what is seen with respect to the 
specificity of FGFs for their receptors [35, 51] and borne out by an analysis of nine FGFs 
[169]. Indeed, it is possible to identify excellent binding structures in sulfated 
polysaccharides that are unrelated to GAGs [196]. This indicates that it is the spatial 
disposition of sulfate, carboxyl and hydroxyl groups on the polysaccharide that are important 
for binding. This also is likely to underlie the observation that, in addition to its classic 
pentasaccharide binding sequence [174], which has been the underpinning of arguments for 
absolute specificity of protein-HS interactions, there are good antithrombin III binding 
structures with anticoagulant activity that are substantially different [186, 197]. The 
evolutionary divergence and, within FGF subfamilies conservation of HS binding properties, 
indicates that they are likely to have functional importance. This is suggested by the 
measurement of the diffusion of FGFs in pericellular matrix [171], which shows that the 
diffusion properties of FGF are determined at least in part by their binding specificities for 
GAGs and by the crosslinking of HS chains by FGF2, but not by FGF9, which has just a 
single HBS [198]. 
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Table 1 Nomenclature and structures of chemically modified heparin structures. 
 
Letter I stands for iduronate, and A stands for the amino sugar glucosamine. 
a
 Numbers refer 
to the ring position of carbon atoms. 
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Figure 1 Stabilization effect of heparin on FGF3. Differential scanning fluorimetry of 5 
μM FGF3 in the presence of varying concentrations of heparin. A, melting curve profiles of 
FGF-3 (5 μM) with a range of heparin concentrations (0-100 μM). B, first derivative of the 
melting curves of FGF-3 in A. C, peak of the first derivative of the melting curves from B, 
which is the melting temperature, Tm (mean of triplicate ±S.E.). D, the curve of melting 
temperature of five FGFs (FGF3, FGF10, FGF4, FGF17 and FGF20). 
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Figure 2 Differential scanning fluorimetry analysis of binding of GAG derivatives to 
FGF3. Differential scanning fluorimetry was performed with a range of heparin-based poly- 
and oligosaccharides with 5 μM protein and 10 μM sugar and the thermal stabilisation 
relative to the PBS control (=0) and heparin (=1) was calculated (see "Experimental 
Procedures"). A, thermal stabilization effect of chemically modified heparins (D2–D9), and 
other glycosaminoglycans (HS, HA, CS, and DS. B, heparin-derived oligosaccharides, 
ranging from dp 2 to dp 12. C, cation-modified heparin forms. Results are the mean of 
triplicates after normalization ±S.E., and an apparent absence of error bar is due to a small 
S.E. 
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Figure 3 Differential scanning fluorimetry analysis of binding of GAG derivatives to 
FGF10. Differential scanning fluorimetry was performed with a range of heparin-based 
poly- and oligosaccharides with 5 μM protein and 10 μM sugar and the thermal stabilisation 
relative to the PBS control (=0) and heparin (=1) was calculated (see "Experimental 
Procedures"). A, thermal stabilization effect of chemically modified heparins (D2–D9), and 
other glycosaminoglycans (HS, HA, CS, and DS). B, heparin-derived oligosaccharides, 
ranging from dp 2 to dp 12. C, cation-modified heparin forms. Results are the mean of 
triplicates after normalization ±S.E., and an apparent absence of error bar is due to a small 
S.E. 
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Figure 4 Differential scanning fluorimetry analysis of binding of GAG derivatives to 
FGF4. Differential scanning fluorimetry was performed with a range of heparin-based poly- 
and oligosaccharides with 5 μM protein and 10 μM sugar and the thermal stabilisation 
relative to the PBS control (=0) and heparin (=1) was calculated (see "Experimental 
Procedures"). A, thermal stabilization effect of chemically modified heparins (D2–D9), and 
other glycosaminoglycans (HS, HA, CS, and DS). B, heparin-derived oligosaccharides, 
ranging from dp 2 to dp 12. C, cation-modified heparin forms. Results are the mean of 
triplicates after normalization ±S.E., and an apparent absence of error bar is due to a small 
S.E. 
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Figure 5 Differential scanning fluorimetry analysis of binding of GAG derivatives to 
HTFGF6. Differential scanning fluorimetry was performed with a range of heparin-based 
poly- and oligosaccharides with 5 μM protein and 10 μM sugar and the thermal stabilisation 
relative to the PBS control (=0) and heparin (=1) was calculated (see "Experimental 
Procedures"). A, the melting temperature of FGF10 in the presence of varying 
concentrations of heparin, Tm (mean of triplicate S.E.). B, the melting temperature of Halo 
protein with and without heparin (2.5 µM and 10 µM). C, Halotag heparin-derived 
oligosaccharides, ranging from dp 2 to dp 12. D, thermal stabilization effect of chemically 
modified heparins (D2–D9), and other glycosaminoglycans (HS, HA, CS, and DS).  Results 
are the mean of triplicates after normalization ±S.E., and an apparent absence of error bar is 
due to a small S.E. 
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Figure 6 Differential scanning fluorimetry analysis of binding of GAG derivatives on 
FGF17. Differential scanning fluorimetry was performed with a range of heparin-based 
poly- and oligosaccharides with 5 μM protein and 10 μM sugar and the thermal stabilisation 
relative to the PBS control (=0) and heparin (=1) was calculated (see "Experimental 
Procedures"). A, thermal stabilization effect of chemically modified heparins (D2–D9), and 
other glycosaminoglycans (HS, HA, CS, and DS). B, heparin-derived oligosaccharides, 
ranging from dp 2 to dp 12. C, cation-modified heparin forms. Results are the mean of 
triplicates after normalization ±S.E., and an apparent absence of error bar is due to a small 
S.E. 
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Figure 7 Differential scanning fluorimetry analysis of binding of GAG derivatives on 
FGF20. Differential scanning fluorimetry was performed with a range of heparin-based 
poly- and oligosaccharides with 5 μM protein and 10 μM sugar and the thermal stabilisation 
relative to the PBS control (=0) and heparin (=1) was calculated (see "Experimental 
Procedures"). A, thermal stabilization effect of chemically modified heparins (D2–D9), and 
other glycosaminoglycans (HS, HA, CS, and DS). B, heparin-derived oligosaccharides, 
ranging from dp 2 to dp 12. C, cation-modified heparin forms. Results are the mean of 
triplicates after normalization ±S.E., and an apparent absence of error bar is due to a small 
S.E. 
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Table 2 
Summary of peptides of FGF3 and FGF10 identified by lysine targeted Protect and 
Label structural proteomics 
Labelled peptides were identified by MALDI-Q-TOF and analysed by MS-digest of the 
package of ProteinProspector v 5.12.3. A full list of identified peptides is provided in the 
supplemental table. The four proteases used for protein digestion were trypsin (TRY), 
thermolysin (THE), chymotrypsin (CHY) and Glu-C (GLU). 
 
 
Figure 8 Position of biotinylated peptides in FGF-3 (residues 56-202) identified by 
structural proteomics mapped onto the predicted three dimensional structure（PDB 
1NUN) and FGF-10 (69-207) from（PDB 1NUN) [199]. Protect and label was used to 
identify the heparin binding sides of FGFs. Labelled peptides are coloured in blue and 
predicted lysines are coloured in yellow. The peptides overlapping with aligned HBS lysines 
are coloured in green.  
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Table 3 
Summary of peptides of FGF4 and FGF6 identified by lysine targeted Protect and 
Label structural proteomics 
Labelled peptides were identified by MALDI-Q-TOF and analysed by MS-digest of the 
package of ProteinProspector v 5.12.3. A full list of identified peptides is provided in the 
supplemental table. The four proteases used for protein digestion were trypsin (TRY), 
thermolysin (THE), chymotrypsin (CHY), Glu-C (GLU). 
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Figure 9 Position of biotinylated peptides in FGF-4 (residues 79-206) and FGF-6 
(residues 47-174) identified by structural proteomics mapped onto the predicted three 
dimensional structure（PDB 1IJT) [200]. Protect and label was used to identify the 
heparin binding sides of FGFs. Labelled peptides are coloured in blue and predicted lysines 
are coloured in yellow. The peptides overlapping with aligned HBS lysines are coloured in 
green.  
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Table 4 
 Summary of peptides of FGF17 identified by lysine targeted Protect and Label 
structural proteomics 
Labelled peptides were identified by MALDI-Q-TOF and analysed by MS-digest of the 
package of ProteinProspector v 5.12.3. A full list of identified peptides is provided in the 
supplemental table. The four proteases used for protein digestion were trypsin (TRY), 
thermolysin (THE), chymotrypsin (CHY), Glu-c (GLU). 
 
 
Figure 10 Position of biotinylated peptides in FGF-17 (residues 33-178) identified by 
structural proteomics mapped onto the predicted three dimensional structure（PDB 
2FDB) [201]. Protect and label was used to identify the heparin binding sides of FGFs. 
Labelled peptides are coloured in blue and predicted lysines are coloured in yellow. The 
peptides overlapping with aligned HBS lysines are coloured in green.  
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Table 5 
Summary of peptides of FGF20 identified by lysine targeted Protect and Label 
structural proteomics 
Labelled peptides were identified by MALDI-Q-TOF and analysed by MS-digest of the 
package of ProteinProspector v 5.12.3. A full list of identified peptides is provided in the 
supplemental table. The four proteases used for protein digestion were thermolysin (THE) 
and chymotrypsin (CHY). 
   
 
 
 
Figure 11 Position of biotinylated peptides in FGF-20 (residues 33-178) identified by 
structural proteomics mapped onto three dimensional structure（PDB 3F1R) [202]. 
Protect and label was used to identify the heparin binding sides of FGFs. Labelled peptides 
are coloured in blue and predicted lysines are coloured in yellow. The peptides overlapping 
with aligned HBS lysines are coloured in green.  
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Figure 12 Sequence alignment of FGF subfamilies: The sequences were aligned with 
ClustalX and Dendroscope [203, 204]. Labelled lysines and overlapped with aligned HBS 
lysines are coloured in blue, predicted lysines and arginines are coloured in red. The aligned 
HBSs are boxed in red. Peptides of both acetylated and biotinylated lysines are coloured in 
green. 
  
 
119 
 
Figure 13 The heparin structural preference of FGFs and their heparin binding sites. *, 
data from Xu et al [34]. 
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Supplemental data 
 
Figure S1 Stabilization effect of heparin on FGF10. Differential scanning fluorimetry of 5 
μM FGF10 in the presence of various concentrations of heparin. A, melting curve profiles of 
FGF-10 (5 μM) with a range of heparin concentrations (0-100 μM). B, first derivative of the 
melting curves of FGF-10 in A. C, peak of the first derivative of the melting curves from B, 
which is the melting temperature, Tm (mean of triplicate ±S.E.).  
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Figure S2 Stabilization effect of heparin on FGF4. Differential scanning fluorimetry of 5 
μM FGF4 in the presence of various concentrations of heparin. A, melting curve profiles of 
FGF-4 (5 μM) with a range of heparin concentrations (0-100 μM). B, first derivative of the 
melting curves of FGF-4 in A. C, peak of the first derivative of the melting curves from B, 
which is the melting temperature, Tm (mean of triplicate ±S.E.). 
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Figure S3 Stabilization effect of heparin on HT-FGF6. Differential scanning fluorimetry 
of 5 μM HT-FGF6 in the presence of various concentrations of heparin. A, melting curve 
profiles of HT-FGF6 (5 μM) with a range of heparin concentrations (0-100 μM). B, first 
derivative of the melting curves of HT-FGF6 in A. 
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Figure S4 Stabilization effect of heparin on FGF17. Differential scanning fluorimetry of 5 
μM FGF17 in the presence of various concentrations of heparin. A, melting curve profiles of 
FGF-17 (5 μM) with a range of heparin concentrations (0-100 μM). B, first derivative of the 
melting curves of FGF-17 in A. C, peak of the first derivative of the melting curves from B, 
which is the melting temperature, Tm (mean of triplicate ±S.E.). 
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Figure S5 Stabilization effect of heparin on FGF20. Differential scanning fluorimetry of 5 
μM FGF20 in the presence of various concentrations of heparin. A, melting curve profiles of 
FGF-20 (5 μM) with a range of heparin concentrations (0-100 μM). B, first derivative of the 
melting curves of FGF-20 in A. C, peak of the first derivative of the melting curves from B, 
which is the melting temperature, Tm (mean of triplicate ±S.E.). 
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Figure S6 The average molecular mass per volume unit volume and the differential 
refractive index of FGF20. The red line shows the different reflective index (dRI). The 
blue line indicates the molecular mass of FGFs. 
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Table S1 
Summary of peptides of FGFs identified by lysine targeted Protect and Label structure 
proteomics 
Labelled peptides were identified by MALDI-Q-TOF and analysed by MS-digest of the 
package of ProteinProspector v 5.12.3. A full list of identified peptides is provided in the 
supplemental table. Four proteases used for protein digestion were trypsin (TRY), 
thermolysin (THE), chymotrypsin (CHY), Glu-c (GLU) and mixture of trypsin and Glu-C 
(TG). 
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Chapter 5 Characterization of HBS mutants of FGF2 
5.1 Introduction 
The heparin binding surfaces of FGF2 have been identified and classified into three 
heparin binding sites (HBS) 
[42, 170, 205]
. The canonical heparin binding site (HBS1) is 
formed by the residues located on strand β1/ β2 loop, strand β10/ β11 loop, strand 
β11 and strand β11/ β12 loop [170]. The secondary HBS2 of FGF2 was identified and 
located to the region 
115
YRSRKYSSWYVA
126 [42, 205]
, whilst a third heparin binding 
site (HBS3) in FGF2 has been found at the N terminus of strand β1 [170]. HBS2 has 
been suggested on the basis of competition by peptides to bind heparin more strongly 
than HBS3 
[42]
. The peptide 
117
SRKYSSWYVA
126 
corresponding to HBS2 was 
found to have low affinity for heparin (KD, 120 ± 50 µM) and it was not able to 
inhibit the bioactivity of FGF2 
[205]
. The significant reduction in the mitogenic 
activity caused by truncation of the N terminus of FGF2 might show an important 
role of HBS3 
[206]. However, this truncation removed part of strand β1 and likely 
destabilised the protein, which would be expected to affect the mitogenic activity. 
To characterize the secondary HBSs and gain an insight into their function, two 
cDNAs were constructed coding for FGF2 mutants (HBS2 and HBS3). The lysines 
identified in HBS2 or HBS3 and adjacent arginines were replaced with alanine. This 
would remove the primary driver of the protein-polysaccharide interaction: ionic 
bonding of the side chains of these basic residues with sulfate and carboxylic acid on 
the polysaccharide. The effect, if any, of the mutations on the heparin structures 
required for binding was measured by differential scanning fluorimetry (DSF). Even 
the Tm stabilisation of FGF-2 is not directly related to activity, the Tm is used as 
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means of detecting binding, not as some predictor of activity 
[196]
. Measurements of 
phosphorylation of p42/44
MAPK
 mitogen-activated protein kinase and cell growth 
were also performed to determine effects on the biological activity of the HBS 
mutations. 
 
5.2 Methods 
5.2.1 Production of FGF2 mutants 
The cDNAs encoding FGF2 secondary HBS mutants were designed: FGF2 (HBS2) 
(208K/A, 219K/A, 249R/A, 251R/A, 252K/A) and FGF2 (HBS3) (160K/A, 163K/A, 
164R/A). The detail of sub-cloning, expression and purification of FGFs from 
cDNAs is described in Chapter 3. 
5.2.2 Differential Scanning Fluorimetry (DSF) 
The melting temperatures of FGF2 mutants (HBS2 and HBS3) were determined with 
heparin (0-500 µM), heparin-derived oligosaccharides of different degrees of 
polymerization (dp), from dp 2 to dp 12, chemically modified heparin derivatives 
D1-D9, porcine mucosal HS, HA, CS, DS, and cation modified heparin as described 
in Section 2.9. 
5.2.3 Phosphorylation of p42/44
MAPK
 
The stimulation of phosphorylation of p42/44
MAPK
 was measured in Rama (rat 
mammary) 27 fibroblasts, as described 
[171]
. Briefly, cells were cultured until near 
confluent in 10 cm diameter dishes. After washing with sterile phosphate-buffered 
saline (PBS), the dishes were incubated with 10 mL step-down medium (DMEM 
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with 0.75 % (w/v) sodium bicarbonate, 20 mM L-glucosamine and 250 µg/mL BSA) 
for 24 h and then replaced with fresh step-down medium (9.5 mL) for another three 
hours. FGF2, FGF2 (HBS2) and FGF2 (HBS3) (final concentration: 200 pg/mL) 
were added to Rama 27 cells and incubated for 15 min and 1h. Afterwards, the cells 
were washed with ice-cold PBS twice and then collected by scraping in lysis buffer 
(20 % (v/v) glycerol, 4 % (w/v) SDS, 10 % (v/v) 2-mercaptoethanol in 120 mM Tris-
Cl, pH 6.8 and coloured with 5 % (w/v) beta-bromophenol blue). The cell lysates 
were heated for 10 min at 98°C. 
5.2.4 MTT assay 
The Rama (rat mammary) 27 fibroblasts was incubated in 10 cm diameter dishes 
until near confluent. After detaching from dishes with trypsin, the cells were seeded 
in a 96-well plate at a density of 3,000 cells per well and cultured for 24 h at 37°C. 
Cell medium was replaced by 100 µL fresh SD medium and incubated for 24 h at 
37°C. FGF2, FGF2 (HBS2) and FGF2 (HBS3) were then added to a final protein 
concentration of 10 ng/mL. In some cases heparin or dp 12 oligosaccharide were also 
added, as indicated in the figure legends. After 48 h incubation, 5 µL MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) reagent (5 mg/mL) was 
added for 4 h. The dye was solubilized by the addition of 50 µL 10 % (w/v) SDS-Cl 
solution overnight at 37°C. The absorbance of each well was read in a spectrometer 
at 570 nm. Results were the mean values of experiments in quadruplicate.  
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5.3 Results and Discussion 
5.3.1 The sugar structure required for binding to FGF2 mutants 
The measurement of thermal denaturation by DSF of FGF2 and its HBS2 and HBS3 
mutants in the presence of different concentrations of heparin concentrations (0- 100 
μM) showed a concentration-dependent effect on the thermal stability of all three 
proteins. The melting temperatures of FGF2 (HBS2) and FGF2 (HBS3) were 35°C 
and 45°C, respectively, while that of wild-type FGF2 (around 55°C) was 
considerably higher ( Fig. 5.2) and similar to that found previously 
[190]
. Thus, both 
of the FGF2 mutants are less stable than wild-type FGF2 in the absence of heparin 
and the melting temperature of FGF2 (HBS2) is even lower than body temperature. 
One explanation is that the replacement of lysine and arginine with alanine (HBS2, 
K208A and R249A; HBS3, K163A and R164A), may create hydrophobic pockets, 
since the basic residues have longer alkyl chains than alanine. For example, a 
potential hydrophobic pocket is formed by the replacement of Arg-249 by alanine in 
the FGF2 (HBS2) (Fig. 5.1). 
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Figure 5.1 The crystal structure of FGF-2 (residues 143-288; PDB 2FGF) 
(Zhang et al., 1991). The green highlighted area in FGF2 and FGF2 (HBS2) are 
Arg-249 (A) and Ala-249 (B), respectively. C and D are the surface electronic 
distribution of FGF2 and FGF2 (HBS2), respectively. Figure rendered using Pymol, 
with the coordinates of 2FGF used to generate the structure of the FGF2 R249-A 
mutant. 
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In the presence of heparin, the thermal stability of wild-type FGF2 was increased to 
78°C, which is similar to previous measurements 
[190]
. The two HBS mutants were 
also stabilised by heparin, which is not surprising, since they still possess an intact 
HBS1. The melting curves show that heparin stabilised FGF2 (HBS2), starting from 
0.4 μM heparin (heparin-FGF molar ratio, 12.5:1) and reaching the maximum 
melting temperature at 100 μM heparin (heparin-FGF molar ratio: 10:1) (Fig. 5.2). 
Although the stabilising effect of heparin on FGF2 (HBS3) was similar to the effect 
on FGF2 (HBS2), beginning at 0.4 μM heparin, it reached a maximum at 5 μM 
heparin (heparin-FGF molar ratio: 1:1) and did not change at higher concentrations 
of heparin. Since the maximum melting temperatures attained in the presence of 
heparin of FGF2, FGF2 (HBS2) and FGF2 (HBS3) were 78°C, 75°C and 80°C, 
heparin is able to stabilise FGF2 and its mutants to similar extents, though the lower 
initial stability of FGF2 (HBS2) seems to reduce the stability attained in the presence 
of heparin.  
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Figure 5.2 Melting temperature curves of FGF2 (blue), FGF2 (HBS2) (black) 
and FGF2 (HBS3) (red). Differential scanning fluorimetry of 5 μM FGF2 (blue), 
FGF2 (HBS2) (black) and FGF2 (HBS3) (red) in the presence of various 
concentrations of heparin (0-100 μM). Results are the mean of triplicates ±S.E. 
The effect of mutating HBS2 and HBS3 on the specificity of FGF2 for different 
sugar structures was then explored. In the case of FGF2 (HBS2), both the single 
desulfated heparin D2 (2-O-sulfate and 6-O-sulfate) and D4 (2-O-sulfate and N-
sulfate) stabilised FGF2 (HBS3) to 80 % and 100 %, respectively, of the level 
observed with heparin respectively, whereas D3 (6-O-sulfate and N-sulfate) only 
stabilised FGF2 (HBS3) half as effectively as heparin (Fig. 5.3A). Although the 
thermal stabilisation effect of any doubly desulfated heparins with either 2-O-sulfate 
or 6-O-sulfate on FGF2 (HBS2) was less than that seen with the singly desulfated 
heparins, the heparin with just N-sulfate (D7) achieved a stabilisation effect on FGF2 
(HBS2) similar to HS and D3. There was a slight binding of FGF2 (HBS2) to DS, 
but no detectable interaction to HA or to CS. FGF2 (HBS2) did not interact with dp 
4 and a dp 6 was the minimum size of oligosaccharide required for stabilising FGF2 
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(HBS2). A dp 12 oligosaccharide imparted the same stabilisation to FGF2 (HBS2) as 
full length heparin (Fig. 5.3B). FGF2 (HBS2) did not distinguish between the 
different cationic forms of heparin (Fig. 5.3C). Thus, both FGF2 (HSB2) and wild-
type FGF2 prefer to bind to the combination of 2-O-sulfate and N-sulfate than to 
other singly desulfated structures, however, they have different preferences for 
singly sulfated structures. FGF2 has a weak interaction with N-sulfated heparin and 
no interaction with 6-O-sulfated heparin, whereas FGF2 (HBS2) has a considerably 
stronger interaction with N-sulfated heparin and a weak interaction with 6-O-sulfated 
heparin. 
FGF2 (HBS3) was more effectively stabilised by any of the singly desulfated 
heparins (D2, D3 and D4) than any of the doubly desulfated heparins (D5, D6 and 
D7) (Fig. 5.3A). The single desulfated heparin D2 and D3 stabilised FGF2 (HBS3) 
to 57 % and 34% of the level observed with heparin respectively, whereas D4 (2-O-
sulfate and N-sulfate) stabilised FGF2 (HBS3) to the same extent as heparin. 
Therefore, FGF2 (HBS3) prefers to bind structures containing 2-O-sulfate and N-
sulfate, such as wild-type FGF2 
[40, 160, 190]
. For singly sulfated heparins (D5, D6 and 
D7), there was only a small stabilising effect on FGF2 (HBS3). Similar to D2 and 
D3, HS stabilised FGF2 (HBS3) to 64 % of the level seen with heparin. However, 
FGF2 (HBS3) did not show a detectable interaction with HA or CS, but DS clearly 
does bind, albeit not as well as HS. The minimum size of oligosaccharide required to 
stabilise FGF2 (HBS3) was dp 8. A dp 12 could stabilise FGF2 (HBS3) as 
effectively as full length heparin (Fig. 5.3B). FGF2 (HBS3) did not bind differently 
to any of the different cationic forms of heparin like FGF2 (HBS2) (Fig. 5.3C). Thus, 
while FGF2 (HBS3) binds similar structures as wild-type FGF2, it required a 
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substantially longer oligosaccharide (wild-type FGF2 binds dp 4, whereas FGF2 
(HBS3) required a dp 8 as the minimum binding structure). 
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Figure 5.3 Differential scanning fluorimetry analysis of binding of GAG 
derivatives to FGF2 (HBS2) (black) and FGF2 (HBS3) (red). Differential 
scanning fluorimetry was performed with a range of heparin-based poly- and 
oligosaccharides with 5 μM protein and 175 μg/ml sugar and the thermal 
stabilisation relative to the PBS control (=0) and heparin (=1) was calculated. A, 
thermal stabilisation effect of chemically modified heparins (D2–D9), and other 
glycosaminoglycans (HS, HA, CS, and DS); B, heparin-derived oligosaccharides, 
ranging from dp 2 to dp 12; C, cation-modified heparin forms. Results are the mean 
of triplicates after normalization ±S.E., and an apparent absence of an error bar is 
due to a small S.E. 
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5.3.2 Biological activities of FGF2 and its HBS mutants on Rama 27 fibroblasts  
The biological activities of the HBS2 and HBS3 mutants of FGF2 were measured 
and compared to those of wild-type FGF2. Since FGF2 prefers to bind FGFR 1c and 
FGFR 3c 
[35]
, FGF2 and its mutants were tested on Rama 27 fibroblasts which 
express FGFR 1c 
[207]
. After stimulation of quiescent Rama 27 cells with FGF2 (200 
pg/mL) for 10 min or 60 min, two strong bands corresponding to dually 
phosphorylated p42/44
MAPK
 were observed after 10 min, which had decreased in 
intensity by 60 min, as seen previously 
[121, 123, 208]
 (Fig. 5.4A). The mutants (HBS2, 
HBS3) also resulted in a similar stimulation of phosphorylation p42/44
MAPK 
in cells 
after 10 min (Fig. 5.4A). However, after 60 min stimulation with FGF2 (HBS2), the 
level of phosphorylation of p42/44
MAPK 
had returned to basal levels (Fig. 5.4A). Thus, 
FGF2 (HBS2) seemed not to promote a sustained plateau of phosphorylation 
p42/44
MAPK 
after the initial early peak, in contrast to wild-type FGF2 (Fig. 5.3A 
[121, 
123, 208]
) and to FGF2 (HBS3). This may reflect the lower stability of FGF2 (HBS2), 
shown by DSF (Fig. 5.2). Since heparin stabilises FGF2 (wild type and mutants), the 
same ratio of heparin: FGF2, which was found to maximally stabilise FGF2, was 
applied to cells to determine if the low stability of FGF2 (HBS2) was the reason for 
its inability to stimulate the phosphorylation p42/44
MAPK 
for 60 min. The activity of 
FGF2 was equivalent to that of FGF2 with heparin, which showed that heparin did 
not affect the stimulation of phosphorylated p42/44
MAPK 
(Fig. 5.4B) 
[121, 178]
. In the 
presence of heparin, which stabilises FGF2 (HBS2) to the same extent as heparin 
(Fig. 5.4B), the stimulation of phosphorylation p42/44
MAPK 
at 60 min by FGF2 
(HBS2) was now apparent. To explore in more depth the effect of stability of FGF2 
(HBS2) on the stimulation of phosphorylation of p42/44
MAPK
 on Rama 27 cells, a 
more complete kinetic analysis was performed (Fig. 5.4C). The phosphorylation of 
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p42/44
MAPK 
reached a maximum at 5 min after the addition of FGF2 and the initial 
peak of phosphorylation declined to a sustained plateau between 30 min and 60 min. 
When Rama 27 cells were stimulated with FGF2 (HBS2), the level of 
phosphorylation of p42/44
MAPK
 also reached maximum levels after 5 min, but then 
declined from 20 min to 60 min, at which time it was still above basal level. Thus, 
there were still differences in the sustained phosphorylation of p42/44
MAPK
 by FGF2 
(HBS2) and wild-type FGF2. These may be due to the mutation of HBS2. However, 
it is also possible that the amount of heparin used to stabilise the FGF2 (HBS2) was 
insufficient, because there are considerable numbers of heparin binding sites on cells 
[209]
, which would therefore decrease the effective concentration of free heparin 
available to stabilise the mutant FGF2. 
The stimulation on cell growth of Rama 27 fibroblast by wild-type FGF2 and FGF2 
(HBS3) was measured using the MTT assay. In contrast to non-stimulated cells, the 
wild-type FGF2 and FGF2 (HBS3) stimulated the incorporation of MTT by almost 
two fold (Fig. 5.4). Even though FGF2 (HBS3) is less stable than wild type FGF2, it 
is clearly sufficiently stable to stimulate cell growth to almost the same extent as 
wild type FGF2. This indicates that HBS3 does not directly affect the intracellular 
signalling process that is required for stimulation of cell growth by FGF2. 
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Figure 5.4 Kinetics of phosphorylation of p42/44 
MAPK
 induced by FGF2 and its 
mutants. Cells were grown in 10 cm diameter dishes and incubated in step-down 
medium for 24 h as described in Section 5.2.2. A, stimulation of p42/44
MAPK
 
phosphorylation by FGF2, FGF2 (HBS2) and FGF2 (HBS3). FGF2 and its mutants 
(200 pg/mL) were applied to cells for 10 min or 60 min.; B, stimulation of 
p42/44
MAPK
 phosphorylation by FGF2 and FGF2 (HBS2) (200 pg/mL) with 300 pg/ 
mL heparin and FGF2 without heparin. C, Time-course of stimulation of p42/44
MAPK
 
phosphorylation by FGF2 and FGF2 (HBS2) between 0 min and 60 min. The blots 
were re-probed with anti-actin to indicate the level of gel loading. 
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Figure 5.5 Incorporation of MTT by Rama 27 fibroblasts stimulated by FGF2 
or its mutant. Cells were seeded in 96 wells plate at a density of 3,000 cells per well, 
as described in the methods. After incubation in SD medium for 24 h, the cells were 
treated with 10 ng/mL wild-type FGF2 and FGF2 (HBS3) for 48 h. The cells were 
mixed with 5 µL MTT reagent (5 mg/mL) for 4 h and then stop solution (50 µL 10 % 
(w/v) SDS-Cl) was added overnight. The absorbance was read at 570 nm in a 
spectrometer. The control groups are cells treated with SD medium only. Results are 
the mean ± S.E of quadruplicate wells. 
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5.4 Conclusions 
Two FGF2 mutants (HBS2 and HBS3) were constructed and produced to gain an 
insight into the secondary HBSs and their function. The secondary binding site 
HBS2 and HBS3 were mutated by the replacement of lysines and arginines with 
alanines in FGF2 (HBS2) and FGF2 (HBS3), respectively. Both mutants were 
charaterised by differential scanning fluorimetry (DSF) to determine the various 
features of heparin structures required for optimum binding; as measured by the 
effect of oligosaccharide binding on the Tm of the FGFs. Both of the FGF2 mutants 
were found to have a lower melting temperature than wild-type FGF2 in the absence 
of heparin. The lower stability particularly of FGF2 (HBS2) may be due to the 
choice of alanine as a substitute for lysines and arginines, which may result in the 
formation of hydrophobic pockets (Fig. 5.1). When compared to wild-type FGF2, the 
classic sulfation pattern required for binding to heparin 
[40, 41, 160]
 of the two mutants 
was not changed, which indicated the driving role of HBS1 in the interaction 
between FGF2 and heparin/HS. However, binding of the mutants to heparin 
structures with lower levels of sulfation or of restricted length was not identical to 
that seen with wild-type FGF2. For example, FGF2 (HBS2) bound more strongly to 
N-sulfated heparin compared to wild-type FGF2. Both FGF2 (HBS2) and FGF2 
(HBS3) required a larger oligosaccharide for minimal binding than did wild-type 
FGF2. It is not clear to what extent these differences are due to an absence of HBS2 
and HBS3 between the mutants and the wild type protein. One interpretation of these 
differences is that they reflect a lower rebinding capacity for the polysaccharide by 
the mutants. Thus, in the case of oligosaccharides, following dissociation, they might 
rapidly rebind the FGF2. There is some evidence for this from protect and label 
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experiments, where some lysines are found to be both acetylated and biotinylated 
[170]
. This is due to transient dissociation from the heparin of one lysine in the HBS, 
during which time it reacts with the protection reagent, NHS acetate. In the mutants, 
rebinding after more substantial dissociation (of more than one lysine) may involve a 
different HBS, so reducing the number of HBSs reduces the rebinding capacity. In 
the case of small oligosaccharides such as dp 6, their rebinding may involve their 
interaction with HBS2 or HBS3 after dissociation and then they could then migrate 
across the surface of the FGF2 back to HBS1. Such movement of the polysaccharide 
on a protein surface has been proposed for neuropilin-I 
[194]
. The biological activities 
of FGF2 and FGF2 mutants were also measured in terms of their stimulation on the 
phosphorylation of p42/44
MAPK
 mitogen-activated protein kinase and cell growth, the 
latter reported by incorporation of MTT. FGF2 mutants could stimulate the 
phosphorylation of p42/44
MAPK
 in a similar manner as wild-type FGF2. However, 
the lower stability of FGF2 (HBS2) confounded this result, since alone it was unable 
to stimulate longer-term phosphorylation of p42/44
MAPK
. By including heparin to 
stabilise FGF2 (HBS2), it was shown that the lack of stability of this mutant is likely 
to be responsible for this difference. Taken together with the similar results for 
p42/44
MAPK
 phosphorylation and cell proliferation induced by FGF2 and FGF2 
(HBS3), the results suggest that HBS2 and HBS3 may not be involved directly in 
generating these cellular responses. In another study, the secondary binding sites of 
FGFs were shown to have the capacity to cross-link HS chains. This may affect the 
movement of the FGF2 in extracellular matrix 
[198]
. In turn cross-linking of HS 
chains by FGF2 could result in the confined motion rather than diffusive motion, as 
observed in pericellular matrix 
[178]
. This may have two consequences. First, the 
HBS2 and HBS3 mutants of FGF2 may diffuse differently in the pericellular matrix, 
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which would affect the types of gradients they are capable of forming. Secondary, 
because they may as a result be less susceptible to trapping in the extracellular 
matrix, in cell culture they would spend more time proportionally in the bulk culture 
medium compared to wild-type FGF2, where their lower stability (especially that of 
FGF2 (HBS2)) would result in their denaturation and loss of activity. 
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Chapter 6 Arginine-targeted protect and label 
6.1 Introduction 
The technique called “protect and label” used in Chapter 6 was developed by Ori et 
al., 
[170] 
to selectively label lysine side chains directly involved in heparin binding, 
that are protected by interaction with the polysaccharide. However, it is not robust 
for heparin binding sites which are rich in arginine, but have few or any lysines. For 
example, the predicted HBS1 of FGF22 includes one lysine, with the remainder of 
the basic side chains being contributed by arginine residues (Fig. 6.1). Indeed, in the 
FGF7 subfamily, the alignment of sequences considered to contribute to heparin 
binding sites indicates that there are many arginine residues. For the characterisation 
of such heparin binding sites, an arginine targeted technique is required, which is the 
focus of this Chapter. For completing the process of protection and labelling, two 
chemicals specific to the guanidino chain of arginine are needed. Phenylglyoxal 
(PGO) has been used as an arginine specific to reagent in the inhibition of chloride 
and sulfate equilibrium exchange across human red cells 
[210, 211]
. A reversible bond 
is created when the glyoxal reacts with arginine residues at 2:1 ratio 
[212]
, whereas, an 
irreversible bond was formed when the ratio of glyoxal and arginine was 1:1 
[213]
 
(Fig. 6.2). Thus, there are potentially at least two products from this reaction. For the 
labelling part, another arginine specific reagent was used, 4-azidophenylglyoxal 
(APG), which has the same dicarbonyl moiety as phenylglyoxal. The inhibition by 
APG of enzymes which have arginine at active sites has demonstrated its ability to 
react with the arginine side chain 
[214]
, while the azido group of APG could be 
photolysed with UV light to produce an unstable nitrene that reacts with 
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nucleophiles, which was used in a cross-linking step 
[215]
.  The azido group of APG 
has also been shown to react with alkynes by click chemistry to form triazoles 
[216]
 
(Fig. 6.3). Biotin DIBO, a strained cyclooctyne from Life Technologies would then 
be used as the alkyne for a copper-free click reaction with the azide structure and the 
biotin group would thus enable the purification of labelled peptide. Therefore, 
phenylglyoxal and triazole production were chosen for the development of an 
arginine targeted protect and label method. 
 
Figures 6.1 Sequence alignment of the FGF7 subfamily: Lysines and overlapped 
with aligned HBS lysines are coloured in blue, arginines predicted from sequence 
alignment are coloured in red. The aligned HBSs are boxed in red. Peptides of both 
acetylated and biotinylated lysines are coloured in green (data from Chapter 4 and 
[34]
). The sequences were aligned with ClustalX and Dendroscope. 
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Figure 6.2 Reaction between arginine (Arg) and phenylglyoxal (PGO). A. the 
guanidyl group of arginine reacts with the dicarbonyl moiety of phenylglyoxal to 
form a Schiff’s base; B. The complex can react with a further phenylglyoxal to form 
alternative structures at a ratio of Arg and PGO of 1:2 
[214]
. 
 
Figure 6.3 Reaction between P-azidophenylglyoxal (APG) and biotin DIBO 
alkyne. A. p-Azidophenylglyoxal monohydrate (APG); B. Biotin DIBO alkyne; C. 
The azide group of APG reacts with the alkyne of biotin DIBO to form a triazole 
structure by click chemistry.  
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6.2 Materials and methods 
6.2.1 Materials 
Peptides (FA, BK, NA) (Table 6.1) and phenylglyoxyl (PGO) were purchased from 
Sigma-Aldrich. Azidophenylglyoxal monohydrate (APG) was purchased from 
Bioworld (Bioquote Ltd, York, UK). 
Table 6.1 The peptides used to develop arginine selective labelling. pGlu, 
pyroglutamyl peptide. 
 
 
6.2.2 Arginine targeted ‘protect and label’ 
Phenylglyoxal monohydrate (PGO) was dissolved in DMSO (dimethyl sulphoxide) 
to 4 M as stock, and then adjusted to the required concentration with PBS (137 mM 
NaCl, 2.7 mM, KCl, 10 mM Na2HPO4 • 2 H2O, 2.0 mM KH2PO4, pH 7.4). A series 
of concentrations of phenylglyoxal were reacted with peptide FA (1.5 μg), which 
includes two arginine residues for different reaction times at room temperature in the 
dark. Various concentration of p-azidophenylglyoxal (APG) were prepared in PBS 
and similarly reacted with peptide FA (1.5 μg). The labelled peptides were purified 
with C18 Zip Tips and analyses were performed on a MALDI-TOF mass 
spectrometer (Waters-Micromass, Manchester, UK) (Section 2.10 .5). Peptides were 
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analysed using a saturated solution of alpha-cyano-4 hydroxycinnamic acid in 50 % 
acetonitrile/0.1 % trifluoroacetic. Peptides were selected in the mass range of 1000-
3500 Da. Data analysis was performed using Mascot. 
 
6.3 Results 
6.3.1 Method development for arginine protection by phenylglyoxal 
The first step in arginine targeted ‘protect and label’ is the protection of arginines 
that are exposed to solvent, because, they are not involved in heparin binding. Since 
phenylglyoxal has been shown to specifically react with arginine side chains, it was 
chosen to block exposed arginines. First of all, a series of concentrations of 
phenylglyoxal were tested with peptide FA, which contains two arginines, for 
different reaction times in order to identify the conditions required for the reaction to 
go to completion (Table 6.2). Two reaction times (5 min and 30 min) were used, 
each with five different concentrations of phenylglyoxal. Peptide FA was 
unmodified after reaction with either 50 mM or 100 mM phenylglyoxal for 5 min 
(Figs 6.8A and B), which indicated that neither of these two concentrations was able 
to provide full protection over this time. Similarly, with 10 mM and 50 mM 
phenylglyoxal and 30 min reaction time (Figs 6.9A and B), not all of arginine 
residues reacted. However, phenylglyoxal at 200 mM modified all of the arginines in 
the FA peptide over 5 min and 30 min (Figs 6.8C and 6.9C). No peak corresponding 
to the peptide was identified when it was reacted with 1M phenylglyoxal (Fig. 6.9D), 
which could be due to the aggregation of peptide induced by the high concentration 
of phenylglyoxal. 
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Table 6.2 Summary of conditions used to react peptide FA with phenylglyoxal. 
 
Peptide FA was reacted with different concentrations of phenylglyoxal, 10 mM (Fig. 
6.9A), 50 mM (5 min, Fig. 6.8A; 30 min, Fig. 6.9B), 100 mM (Fig. 6.8B), 200 mM 
(5 min, Fig. 6.8C; 30 min, Fig. 6.9C) and 1 M (Fig. 6.9D) at room temperature in the 
dark. FA, Fibronectin adhesion-promoting peptide; uFA, FA alone; FA+PGO, 
peptide FA was reacted at a molar ratio of 1:1 with PGO; PGO+2xPGO; peptide FA 
was reacted at a molar ratio of 1:2 with PGO. None, no peptide was detected. No 
peptide was detected when peptide FA was reacted with 1.0 M PGO for 30 min. 
 
Phenylglyoxal at 200 mM could, over 5 min, react fully with the arginines in FA. 
Interestingly, two reaction products of peptide FA were detected: type A was FA 
modified by one PGO, where the ratio of arginine: PGO is 2:1; type B was FA 
modified by two PGO, which was the expected product at a ratio of arginine: PGO 
(1:1) (Fig. 6.4B). One interpretation is that PGO could not protect all the arginines 
when the product was of type A. However, the two arginine residues are close to 
each other and separated by just an alanine residue, which has a short side chain. 
Thus, another possibility could be that the dicarbonyl group of the PGO has reacted 
with the side chains of the two adjacent arginines to form a Schiff’s base and hence 
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the arginines are fully protected. To distinguish these possibilities, modified FA was 
treated with trypsin. Unmodified peptide FA was successfully digested by trypsin 
and the large fragment ‘WQPPR’ was identified (Fig 6.4C). After trypsin digestion 
of modified FA, only the two peptides, which was detected in the absence of the 
digestion, were detected (Fig 6.4D). Thus, the peptides modified with PGO in the 
ratio of arginine: PGO 2:1 and 1:1 were protected from digestion, which means both 
of the arginines are subject to modification by PGO. 
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Figure 6.4 Mass spectra of the digestion of unmodified and modified FA. A. FA, 
Fibronectin Adhesion-promoting peptide; B. Peptide FA was reacted with 200 mM 
phenylglyoxal for 30 min. FA+PGO, peptide FA modified with one PGO; 
FA+2xPGO; peptide FA modified with two PGO. C. unmodified peptide FA 
digested with trypsin. The large part of the sequence was identified as ‘WQPPR’. D. 
modified peptide FA digested with trypsin and only two modified peptides (I and II) 
were detected. 
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It is clear from the above that the position of arginine resides affects the reaction 
product. Peptide BF (Bradykinin Fragment), which has one arginine at its C terminus, 
was used to identify the effect of this position, where the arginine side chain is 
relatively unencumbered (Fig. 6.5A). This peptide was reacted with 200 mM 
phenylglyoxal in the dark for 30 min. Two types of modified peptide BF were 
identified: one peptide with the arginine modified by a single PGO (arginine: PGO, 
1:1); a second peptide with the arginine modified by two PGO (arginine: PGO, 1:2) 
(Fig. 6.5B). Since the arginine at the C terminal has more free space for its side chain, 
the PGO could create a reversible bond at a 2:1 ratio of its dicarbonyl group to 
arginine as described in Takahashi’s study [212]. To establish that this was the case, 
two peptides: peptide I (RPYIL, molecular mass 663.3) and peptide II (LYENKPR, 
molecular mass 1062.0) were produced by treating peptide NA with trypsin. This 
yields one peptide with arginine at the N terminus (peptide I) and another one with 
arginine at the C terminus (peptide II) (Fig. 6.6A). Both peptides were added to 200 
mM PGO in the dark for 30 min. In each case they were modified with one PGO or 
two PGO (Fig. 6.6B).  
The use of peptides with arginine residues in defined contexts demonstrated that 
phenylglyoxal was likely to fully protect all of the arginine residues in a protein 
regardless of the adjacent sequence. The position of arginine in peptides could affect 
the formation of the Schiff’s base and multiple products are clearly produced. 
However, these are resolvable by mass spectrometry. The next step was to determine 
whether azidophenylglyoxal (APG) could similarly fully react with arginine residues.  
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Figure 6.5 Mass spectra of BF reacted with 200 mM phenylglyoxal for 30 min. 
A. BF, Bradykinin Fragment 2-9; B. BF+PGO, peptide BF modified with one PGO; 
BF+2xPGO; peptide BF modified with two PGO. 
Figure 6.6 Mass spectra of peptide I and II reacted with 200 mM phenylglyoxal 
for 30 min. A. NA was digested with trypsin to produce two peptides I (RPYIL) and 
II (LYENKPR). B. I/II+PGO, peptide I/II modified with one PGO; I/II+2xPGO; 
peptide I/II modified with two PGO. 
  
 
154 
6.3.2 Method development of arginine labelling by azidophenylglyoxal (APG) 
The reaction of azidophenylglyoxal was examined before its use to label arginine 
residues protected by binding to heparin. The stock of APG (4 M) was adjusted to 20 
mM, 50 mM or 100 mM with PBS. Owing to the greater hydrophobicity of APG 
compared to PG, it was found that 40 % (v/v) DMSO was required to maintain the 
highest concentration (200 mM) in solution. Reaction of APG at these different 
concentrations with peptide FA was then performed for 30 min in the dark. Two 
major peaks were observed upon MALDI-TOF analysis of the products: unmodified 
peptide FA and peptide FA modified with one APG (Figs 6.11 A, B and C). After 
calculating the mass increase following modification of peptide FA, it would appear 
that the guanidyl group of arginine primarily reacts with the dicarbonyl part of 
phenylglyoxal to form a Schiff’s base complex and this is then followed by a ring 
expansion formed due to the nitrene group reacting with double bonds, which 
normally happens after the photoactivation of APG with UV light 
[217]
 (Fig. 6.10). 
When peptide FA was reacted with APG for longer times (50 mM for 2 h), there was 
still some unmodified peptide FA present (Fig. 6.11D). 
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Figure 6.10 Ring expansion caused by the reaction of the nitrene group with 
double bonds. 
When the highest concentration of APG, 200 mM, was used, peptide FA could be 
modified by one APG or two APG when the reaction was performed for 5 min in the 
dark, whereas in peptide FA modified with a ratio of 1:1 of APG: arginine, was only 
found after 30 min reaction (Fig 6.12). However, unmodified peptide FA was 
identified in both reactions, which means 200 mM APG would not be able to offer 
full arginine labelling. The arginine labelling of azidophenylglyoxal seems be 
affected by the reactivity of the azide, in the context of an adjacent aromatic ring. 
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6.4 Discussion: 
To achieve complete labelling, the conditions for modifying arginine with PGO have 
been optimized. Even though different types of interaction product were identified 
by mass spectrometry, all arginines were found to be labelled using 200 mM PGO. 
The lysine targeted labelling technique has simpler and more predictable chemical 
reactions and is very well established. Thus, it has been used to identify heparin 
binding sites 
[170]
, In contrast, techniques for arginine targeted labelling have not 
been as well developed and this is the first time it has been explored in the context of 
identifying heparin binding sites. Although PGO has been used to block arginine for 
inhibition of enzyme active sites, arginine labelling with PGO has not been 
developed. This may be due to there being more than one reaction product, which 
would have been difficult to distinguish in the past. However, the different products 
are easily identified by mass spectrometry, so this approach can certainly be used in 
the context of omics experiments. 
When APG was used in reactions with arginine, full labelling could not be achieved, 
even at the highest concentration of APG. One major problem was that the azide 
adjacent to the aromatic ring caused a ring expansion reaction, which may reduce the 
solubility of APG and affect its interaction with arginine. Therefore, for further 
development of this method, APG should be first reacted with DIBO-biotin to form 
the triazole structure. This will then prevent the azide reacting intramolecularly with 
this neighbouring aromatic ring. Alternatively, the APG could be replaced by PGO 
with a different reactive group. For example, a thiol group is able to react with 
biotin-maleimide. Though maleimide would also interact with cysteine residues, 
these could be blocked with iodoacetamide before the labelling step. Another 
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solution would be to use PGO and mass tagged PGO for completing protection and 
labelling. 
In conclusion, the principle of the arginine targeted protect and label technique has 
been established. Optimization of the arginine labelling steps remains to be achieved. 
Since all of the measurements conducted here were performed on peptides, the 
optimised arginine-directed protect and label would need to be tested on proteins 
with well-defined heparin binding sites. The FGFs used in Chapter 4 and in Xu et al. 
[34]
, would provide such a test system to validate the method. 
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Figure 6.7 Mass spectra of FA. FA (1.5 μg) was also loaded on MALDI-TOF as 
mass control. The mass of FA is 1025.7. 
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Figure 6.8 Mass spectra of FA reacted with PGO. Peptide FA was reacted with 
phenylglyoxal (A. 50 mM; B. 100 mM; C. 200 mM) for 5 min. FA, Fibronectin 
adhesion-promoting peptide; uFA, FA alone; FA+PGO, peptide FA modified with 
one PGO; FA+2xPGO; peptide FA modified with two PGO.  
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Figure 6.9 Mass spectra of FA reacted with PGO. Peptide FA was reacted with 
phenylglyoxal (A. 10 mM; B. 50 mM; C. 200 mM; D. 1 M) for 30 min. FA, 
Fibronectin adhesion-promoting peptide; uFA, FA alone; FA+PGO, peptide FA 
modified with one PGO; FA+2xPGO; peptide FA modified with two PGO. D. No 
expected peptide was detected. 
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Figure 6.11 Mass spectra of FA reacted with APG. Peptide FA was modified with 
p-azidophenylglyoxal (A. 20 mM; B. 50 mM; C. 100 mM) for 30 min. FA, 
Fibronectin adhesion-promoting peptide; uFA, FA alone; D. FA+APG, peptide FA 
modified with one APG. 
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Figure 6.12 Mass spectrum of modified FA by APG. Peptide FA was modified 
with 200 mM p-azidophenylglyoxal for 5 min (A.) and 30 min (B.) in the dark. FA, 
Fibronectin adhesion-promoting peptide; uFA, unmodified FA; FA+APG, peptide 
FA modified with one APG; FA+2APG/2APG+H2O, peptide FA modified with two 
APG or two APG plus one H2O. 
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Chapter 7 General discussion and perspective 
7.1 Discussion: 
A large number (>883) of extracellular regulatory proteins have been identified as 
heparin binding proteins by virtue of their interaction with heparin 
[113, 114]
. For many 
of these, but not all, their physiological activities will be regulated by HS. FGFs 
often serve as a model for understanding the consequences of the interaction with HS 
of other proteins. The expansion of FGF and FGFR from two or three FGF ligands 
and one fgfr alongside HS in the fly Drosophila and the worm C. elegans to 22 FGFs 
and 5 fgfrs in vertebrates and mammals is reflected in the more complex 
specification required for body structure in mammals. Thus, the expansion and 
diversification of the FGF communication system is likely to have been subjected to 
the same natural selection pressures as those that drove the increasing complexity of 
animal bodies. The specificity of FGF ligands for FGFR isoforms is reflected in the 
evolutionary relationship of the FGF ligands at the level of their phylogeny deduced 
from amino acid sequence. However, the level of specificity of FGFs for binding HS 
is still debated. One school, drawing on the high specificity of the interaction of 
antithrombin III with for a pentasaccharide structure in heparin, contends that there 
are rare and unusual sequences of saccharides in HS, and related heparin, e.g., 
‘GlcNNAc/NS, 6S-GlcA-GlcNNS, 3, 6S-idoUA2s-GlcNNS, 6S’ 
[163]
, responsible for high 
affinity and high specificity binding of the FGFs. This view is somewhat undermined 
by the existence of antithrombin III oligosaccharide binding structures that are not 
identical to the pentasaccharide sequence 
[186, 197]
. Another school contends that 
largely non-specific ion-exchange interactions underpin FGF binding by the sugar. 
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However, this view is also undermined, because the concentration of NaCl required 
for elution of FGFs from a heparin column are higher than that required for elution 
from a strong cation-exchange column 
[171]
. Most of the work on FGFs is not 
systematic. That is, only one or two FGFs and/or a limited repertoire of sugar 
structures have been examined. The one exception is the work of Xu et al., 
[34]
, in 
which the heparin-binding properties of six FGFs from five subfamilies were studied. 
However, one of these FGFs was FGF21, which is an endocrine member of the 
family and, thus, does not bind heparin. Moreover, only for the FGF1 subfamily was 
there more than a single FGF from a subfamily used in this study. Therefore, 
although the conclusion of this work was that the binding of FGFs to heparin-derived 
structures was selective and had followed the evolutionary divergence of the FGF 
family, this was very much a hypothesis that required testing. Therefore, in this 
thesis, the evolutionary relationship of the FGF family was used as a defined system 
to determine the specificity of interactions of FGFs with heparin/HS and other model 
GAGs. Six recombinant FGFs (FGF3, FGF4, FGF6, FGF10, FGF17, and FGF20) 
from 4 subfamilies were produced (Chapter 3) and their interactions with GAGs 
probed. To begin to characterize the functions of the secondary heparin binding sites 
of FGFs, FGF2 with HBS2 or HBS3 mutated to alanine was produced and compared 
to wild-type FGF2. In addition, an arginine targeted protect and label method was 
developed, which will enable the identification of HBSs enriched in arginine 
residues, as these are currently not detectable. 
In Chapter 3, in addition to describing the process of the production of FGF proteins, 
we discovered that N-terminal HaloTag fusions could enhance protein expression 
and stabilise the FGFs. Thus, comparing production of 11 FGF proteins with an N-
terminal HaloTag fusion to those without this, the yield of FGF2, FGF3 and FGF7 
  
 
165 
was found to have been significantly increased. In addition, HaloTag also was found 
to markedly enhance the expression as soluble proteins of FGFs that had hitherto 
been expressed mostly in an insoluble form (FGF3, FGF6, FGF7, FGF8, FGF16, 
FGF17, FGF20, and FGF22). This was a major step forward, particularly in the cases 
of FGF6, FGF8, FGF16, and FGF20 that had previously been reported to be 
expressed mainly in inclusion bodies, and even as truncated proteins 
[218-221]
. Most 
interestingly, HaloTag was able to prevent the toxicity of FGF7, which usually 
requires strong repression, e.g., the use of pLysS, that in turn reduces protein yield 
[222]
. Another advantage of HaloTag is that, thanks to its low isoelectric point, anion-
exchange chromatography could be used to isolate the HaloTag FGFs, which is 
orthogonal to the usual approaches for FGF purification. Subsequent cleavage with 
TEV then allowed the efficient removal of the HaloTag. However, some FGFs 
appear to aggregate after separation from the HaloTag fusion, indicating that these 
are not stable. There is clearly not a universal solution to resolve problems of protein 
expression and for those FGFs that aggregated after cleavage of the Halotag, e.g., 
FGF6, some engineering of the FGF will likely be necessary. The FGFs that express 
as insoluble protein all have long N- and/or C-terminal extensions. An NMR analysis 
of the N-terminus of FGF2 that extends beyond the first beta strand of the beta trefoil 
has shown that it is very flexible 
[223]
. Therefore, an analysis of the relative disorder 
of these regions and judicious trimming may yield protein that does not aggregate 
after cleavage of an expression tag such as HaloTag. 
In Chapter 4, the specificity of interaction with the polysaccharide of six FGFs from 
four subfamilies has been explored at different levels: the heparin structures required 
for binding by FGFs were measured by differential scanning fluorimetry (DSF) and 
the heparin binding sites on FGFs were identified by ‘protect and label’. Along with 
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our existing work on six other FGFs from five FGF subfamilies, there are now at 
least two members of each paracrine FGF subfamily that have been characterized in 
this way. This provides a reasonable coverage of the FGF family (Fig. 1.2). When 
these data are mapped to the FGF phylogenetic tree based on amino acid sequence it 
becomes clear that FGFs from the same subfamily prefer similar sulfation patterns 
and lengths of oligosaccharide, and share similar heparin binding sites compared to 
FGFs from different subfamilies (Fig. 13, Chapter 4). Therefore, it is likely that these 
HS binding properties of the paracrine FGFs were selected for during the divergence 
and expansion of the FGF family that was associated with the evolution of more 
complex animal body plans. It is interesting to note that the specificity of FGFs for 
FGFR isoforms seems also to be associated with the same evolutionary process 
(Table 1.2). With respect to HS binding, it seems clear that there is indeed a good 
degree of specificity and selectivity, but this is not a simple one to one code. The 
same is true for the interactions of FGFs with FGFR isoforms 
[35, 51, 169]
. It is also 
intriguing to note that there exist differences between members of a subfamily in 
terms of their interactions with the polysaccharide, e.g., the likely presence of a 
secondary HBS3 in FGF20, compared to FGF9 that only has a single, enlarged 
HBS1. 
The discovery that the molecular basis of the interaction of FGFs with GAGs has 
been subject to the natural selection process that gave rise to an expanded FGF 
family has important ramifications. One relates to the question of how specific and 
selective protein-GAG interactions are. There are clearly limitations in describing 
the molecular basis of these interactions on the basis of the linear structure of the 
polysaccharide. It is the spatial positions of groups on the sugar that are important 
for binding and the observation that polysaccharides unrelated to HS can bind and 
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also participate in the ternary signalling complex with an FGFR 
[196]
 provides strong 
evidence for this. The sugar chain will adopt a variety of conformations in solution 
and pendant sulfate groups will modify the conformational space that the chain can 
occupy, which has been demonstrated by NMR and CD studies 
[224]
. In addition, the 
coordination of cations modifies the conformation of the polysaccharide chain 
[225]
. 
Finally, while the binding to polysaccharide clearly changes the conformation of the 
protein, e.g., thermal stabilisation observed by DSF, the reverse is also true: binding 
to protein alters the conformation of the polysaccharide. The latter point is elegantly 
made by the co-crystal structure of FGF2 and a heparin dp 6, in which the latter has 
iduronate residues in both the 
1
C4 and the 
2
S0 configurations 
[40]
. Thus, the selectivity 
and specificity identified here is somewhat artificial, since the conformation of HS in 
vivo in extracellular and pericellular matrix will depend on the sequence of 
saccharides, the coordinated cations and the pre-existing interactions of the HS chain 
with endogenous proteins. At some level, cells can sense what functional structures 
they produce and modify these. This is shown by the HS 2-O sulfotransferase 
knockout mouse, which dies at birth due to kidney agenesis 
[226]
. HS or heparin 
lacking 2-O-sulfate cannot bind FGF2 or form a productive ternary complex with the 
FGFR 
[125]
. Yet, the knockout mice have no FGF2 phenotype. Moreover, when 
embryonic fibroblasts were derived from these mice, their HS did not possess any 2-
O-sulfated HS, but the HS was capable of interacting with FGF2 and enabling it to 
bind and activate FGFR on cells 
[227]
. Thus, there are homeostatic mechanisms 
whereby cells can modify the chains they produce and perhaps cations coordinated to 
HS and/or the endogenous proteins bound to this HS, to ensure that as many as 
possible of the appropriate functions are maintained after perturbation. Such 
homeostatic plasticity can be considered to be advantageous, since it provides for a 
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robust, rather than a brittle communication system. However, this clearly limits the 
degree to which one can apply simple interpretations to the molecular basis of 
specificity of FGF-GAG interactions. These considerations are likely to apply to 
many, if not all such interactions, since even the pentasaccharide structure that binds 
antithrombin III which is used as an example of a highly specific interaction has 
alternatives 
[163]
. 
Another ramification of the interaction of FGFs with GAGs being subject to natural 
selection relates to the phylogenetic relationship of the FGFs themselves. In Chapter 
1 (Sections 1.2 and 1.3) two different phylogenetic trees were presented. One is 
based on the idea that genes that are close to each other are likely to reflect a 
conservation of an ancestral genome organization; that is, this is less likely to have 
arisen by chance. The other is based on amino acid sequence homology and again 
this is deemed to reflect a common ancestor, where amino acids important for 
structure and function are considered less likely to change over time and their 
conservation is thus not due to chance. The differences in the two trees relate to the 
positions of FGF3 and FGF5; both trees cannot be correct and one is thus more 
likely to reflect a chance event than the other. The results presented here indicate that 
the phylogeny based on amino acid sequence also reflects conservation of secondary 
GAG-binding sites in the FGFs and preferences for particular binding structures in 
GAGs. Although there are no data on FGF5, the data on FGF3 suggest that it is more 
closely related to the FGF7 subfamily than the FGF4 subfamily, since it has a HBS4 
(only present in FGF7 subfamily) and its preferred binding structures in the model 
GAGs are most similar to FGF7 and FGF10. In addition, work on the preferences of 
FGFs for FGFR isoforms also show a clear relationship between the amino acid 
based phylogeny and FGFR binding. FGF3 and FGF5 are clearly more closely 
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related to the FGF7 and FGF4 subfamilies, respectively, in terms of FGFR isoform 
preference; for example, FGF5, like FGF4 and FGF6, does not bind FGFR1b, 
whereas FGF1 and FGF2 do 
[35, 51]
. The function of FGFs is determined by binding 
to GAGs and FGFR. Natural selection operates on phenotype; it is a particular 
phenotype that has some advantage over others. The data on the HS binding 
preferences of the FGFs, coupled to their FGFR isoform preferences are consistent 
with the phylogeny based on amino acid sequence homology. This suggests that this 
phylogeny may have been less likely to have arisen by chance than that based on 
genome organization. 
The preference of FGFs from different sub-families for distinct sugar structures will 
be an important means for cells to regulate the activities of multiple FGFs, 
independently of each other, in the same tissue. One level at which such regulation 
can occur is at that of the formation of the ternary FGF:HS:FGFR signaling complex 
(Section 1.7). Clearly, if a cell produces HS structures that do not bind members of a 
particular FGF subfamily or an individual FGF, then even if the appropriate (Table 
1.2) FGFR isoform is expressed on that cell, a growth response cannot occur, 
because a ternary complex cannot be formed. Another level of regulation relates to 
the diffusion of FGFR ligands from a source to a target cell. The binding sites in the 
pericellular matrix of Rama 27 fibroblasts were shown to control the diffusion of 
FGF2 
[178]
. An important question raised by this work was whether binding to HS 
might control the diffusion of HS-binding ligands more generally. This question has 
recently been addressed by measurements on the binding and diffusion of five Halo-
FGFs (Halo-FGF1, Halo-FGF2, Halo-FGF6, Halo-FGF10, Halo-FGF20) in the 
pericellular matrix of fixed Rama 27 fibroblasts 
[228]
. Fixed cells were used to ensure 
there were no confounding effects from the membrane and cell movement. The data 
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clearly demonstrate that the binding preferences of FGFs for distinct sugar structures 
determine both their interactions with glycosaminoglycans in the pericellular matrix 
and their diffusion 
[228]
. For example, more Halo-FGF1 bound to the pericellular 
matrix than Halo-FGF2 or Halo-FGF6, which is consistent with FGF1 binding a 
broader range of structures in HS (Figure 13, Chapter 4). Moreover, Halo-FGF20, 
which has very unusual (for an FGF) binding preferences (Figure 13, Chapter 4) 
failed to bind detectably. FGF10 was found to be bound to both HS and CS/DS. 
Interestingly, the expression of binding structures for the different Halo-FGFs 
showed spatial heterogeneity within the pericellular matrix of individual cells, which 
was most pronounced for Halo-FGF10, which bound in patches, separated by areas 
where Halo-FGF10 did not bind. The diffusion of the FGFs that bound to the 
pericellular matrix was also found to be different, with Halo-FGF2 and Halo-FGF6 
diffusing faster than Halo-FGF1. This is likely to be due  to Halo-FGF1 possessing 
more binding sites in the pericellular matrix of these cells 
[229]
. Thus, cells express 
HS chains with a range of structures that can selectively bind different FGFs, and the 
HS chains with particular FGF binding properties are segregated, that is they can be 
localized differently in the pericellular matrix. The regulation of diffusion of FGFs 
by binding to different structures in HS that are distributed heterogeneously in the 
pericellular matrix allow cells to control independently the localization and the 
bioavailability of the multipole FGFs simultaneously.       
In Chapter 5, the mutants of FGF2 (HBS2 and HBS3), in which either HBS2 or 
HBS3 of FGF2 were mutated by replacing the lysines and arginines with alanines, 
have been produced to explore the secondary HBSs and its function. Both mutants 
have been compared to wild-type FGF2 in terms of the heparin structures required 
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for optimum binding and their biological activities on Rama 27 fibroblasts. The 
mutants were found to have a lower stability than wild-type FGF2, which may be 
caused by the hydrophobic pockets formed by the alanines. The mutants were found 
to have similar preference for sulfation patterns. However, differences between wild-
type FGF2 and the mutants were found in their interactions to polysaccharides with a 
low level of sulfation and of restricted length. Compared to wild-type FGF2, FGF2 
(HBS2) binds N-sulfated heparin strongly and both mutants required larger 
structures for minimal binding, which could be due to a reduction of their rebinding 
capacity to the polysaccharide after (partial) dissociation. FGF2 and its mutants have 
been shown to stimulate similarly the phosphorylation of p42/44
MAPK
 and cell 
proliferation, which indicates that the HBS2 and HBS3 of FGF2 may not be directly 
involved in these aspects of FGF signalling. Since the HBSs have been suggested to 
contribute to the cross-linking of HS chains observed in vitro 
[198]
, their role may 
instead be to control the diffusion of FGF2 in extracellular matrix, and be 
responsible for at least some of the confined motion observed previously 
[178]
. 
In Chapter 6, a new arginine targeted ‘protect and label’ technique was developed to 
allow a complete identification of the residues in HBSs involved in ionic bonding. In 
addition, there are some HBSs that only contain arginine and these would then be 
revealed. A first challenge was to distinguish the different reaction products of 
arginine and PGO. This difficulty is likely to underlie the lack of work exploiting 
this chemistry for the identification of arginine residues in binding sites of proteins 
and for labelling proteins. The present work demonstrates that the different reaction 
products are predictable in terms of the position and neighbours of the arginine 
residues and resolvable by mass spectrometry. The result is that the different reaction 
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products should, when the method is applied to proteins, provide additional 
confirmatory information relating to the arginines that are identified.  
However, 4-azidophenylglyoxal (APG), which was used in the labelling step, did not 
react stoichiometrically with arginine residues. This seems to be due to the 
interaction of arginine and APG and the unforeseen side reaction of ring expansion 
reaction due to the azide group adjacent to the aromatic ring. Therefore, the labelling 
step needs to be reconsidered to avoid this side reaction. 
 
7.2 Further work: 
The work done for this thesis highlights a number of areas for future work. These 
relate to the molecular basis of the interaction of FGFs with HS, the functions of the 
secondary binding sites and the development of the ‘protect and label’ approach for 
identifying heparin binding sites in proteins. 
Several aspects of the interaction of the six FGFs used in the present work with HS 
need to be determined. Firstly the binding parameters (KD, and if possible the kinetic 
parameters ka and kd). This was attempted, but these proteins exhibited strong non-
specific binding to surfaces, which precluded using surface-based optical biosensors. 
Solution based methods such as microscale thermophoresis 
[34, 230]
 may enable such 
measurements, although preliminary experiments were not conclusive. Alternatives 
might be to use more robust surfaces for the optical techniques, such as the 2-D 
semi-crystalline arrays of streptavidin assembled on a biotinylated support grafted 
onto gold surfaces 
[198]
. Circular dichroism would provide insight into the 
proportions of secondary structure present in these FGFs in solution and the degree 
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to which this changes upon binding to heparin. In previous work 
[34]
 it was shown 
that the FGFs investigated contained less secondary structure than expected from 
their crystal structure, but that this increased when they bound heparin. The DSF 
data support this, and acquiring direct evidence would lend weight to the idea that 
polysaccharide-induced conformational change in the FGF is important for FGFR 
binding 
[119]
, which may, therefore, be worth revisiting. Clearly, the development of 
an arginine-targeted protect and label method is important and applicable beyond the 
realm of FGFs. The first step would be to optimize the arginine labelling with APG. 
One way to avoid the ring expansion problem would be to first react the APG with 
DIBO-biotin in a so-called “click” reaction. This would remove the azide, and 
should prevent ring expansion. Alternatives would be to use a PGO with a different 
reactive group, such as a thiol group, which is able to react with biotin-maleimide or 
to simply use a mass tagged PGO. 
In the longer term, there are two areas that thesis suggests would be useful to 
investigate.  These relate to the secondary HBS of FGFs, and to the identification of 
heparin binding proteins in the extracellular matrix and understanding how these 
interactions may change either due to physiological challenge or to disease. 
For the characterization of the secondary binding sites of FGFs, the HBS mutations 
need to be redesigned by replacing the lysines and arginines of HBS with amino 
acids identified by alignment with endocrine FGFs, which should avoid the low 
stability of the FGF2 mutants produced in this work. Based on work with FGF2 and 
FGF9, it has been proposed that the secondary HBSs of FGFs are able to cross-link 
HS 
[198]
; this idea could be examined in depth using a combination of FGFs with 
different secondary HBSs and mutants of these. This could then be taken a step 
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further, by measuring the movement of these FGFs (wild-type and mutants) in cell 
pericellular matrix, e.g., Duchesene et al., 2012, to determine whether the ability to 
cross link HS chains is associated with confined motion of FGF. 
With a ‘protect and label’ procedure targeting lysines and arginines it will be 
possible to identify the major ionic contacts in the HBS of proteins.  However, for 
proteins with multiple HBSs, it does not identify, which of these is engaged in vivo 
and whether this might change in the course of a physiological challenge or in 
disease. A proteomics pipeline has been developed to identify heparin-binding 
proteins from tissues 
[114, 156]
. However the weakness of this approach is that it 
cannot distinguish a heparin binding protein from a protein bound to a heparin 
binding protein. In addition, it provides no information on which HBSs are engaged 
with the polysaccharide. This pipeline uses heparin affinity chromatography to 
purify heparin binding proteins followed by their identification using mass 
spectrometry. It should be possible to integrate the ‘protect and label’ strategy into 
this the pipeline. The protection step would be performed on purified extracellular 
matrix and following dissociation of protein-polysaccharide complexes with high 
NaCl, exposed lysines or arginines could then be labelled. While the conditions used 
to dissociate the protein-polysaccharide complexes are likely to require substantial 
optimization, integration of the methods would have several benefits. Firstly, the 
HBSs actually engaged with the polysaccharide would be identified; comparison 
with the proteins isolated by heparin affinity chromatography would then identify 
proteins bound to the heparin-binding proteins. Secondly, a comparison of normal 
versus disease, e.g., pancreas and acute pancreatitis 
[114]
, would yield information not 
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just on changes of levels of proteins, but also changes in their association with GAGs, 
which would provide a much richer insight into the disease process. 
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Papers and manuscripts 
Contributions to work 
Paper 1 
D. J. Nieves, Y. Li, D. G. Fernig, R. Lévy, 'Photothermal raster image correlation 
spectroscopy of gold nanoparticles in solution and on live cells', Open Science, 2 
(2015). 
Produced recombinant FGF-2 protein and contributed to edit paper. 
Paper 2 
E. Migliorini, D. Thakar, J. Kuhnle, R. Sadir, D. P. Dyer, Y. Li, C. Sun, B. F. 
Volkman, T. M. Handel, L. Coche-Guerente, D. G. Fernig, H. Lortat-Jacob, and R. P. 
Richter, 'Cytokines and Growth Factors Cross-Link Heparan Sulfate', Open Biol, 5 
(2015). 
Produced recombinant FGF-2 protein and FGF-9 protein and contributed to edit 
paper. 
Paper 3 
C. Sun, Y. Li, S. E. Taylor, X. Mao, M. C. Wilkinson, and D. G. Fernig, 'Halotag Is 
an Effective Expression and Solubilisation Fusion Partner for a Range of Fibroblast 
Growth Factors', PeerJ, 3 (2015). 
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Contributed to the cloning of cDNA of Histag-FGF3, Histag-FGF7, Halotag/Histag-
FGF16 and Halotag/Histag-17. Expression and Production of FGFs. Assisted with 
biological activities assay. Data analysis. Co-wrote the paper. 
Paper 4 
Q. M. Nunes, Y. Li, C. Sun,  T. K. Kinnunen, D. G. Fernig, 'Fibroblast growth 
factors as tissue repair and regeneration therapeutics', PeerJ, accepted  (2015). 
Contributed to the translation of Chinese papers. Co-wrote the paper. 
Paper 5 
Y. Li, C. Sun, E. A. Yates, M. C. Wilkinson, and D. G. Fernig, 'Heparin binding 
preference and structures in the fibroblast growth factor family parallel their 
evolutionary diversification, Open Biol, Submited (2015). 
Produced recombinant FGF proteins, performed the experiments and drafted the 
entire manuscript. Other authors supplied sugars and FGF proteins. 
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